{"title": "PDF", "author": "PDF", "url": "https://edoc.unibas.ch/104/1/DissB_6804.pdf", "hostname": "PDF", "description": "PDF", "sitename": "PDF", "date": "PDF", "cleaned_text": "PD Dr. Elisabeth Zemp Stutz Prof. Dr. Martin Birkh\u00e4user Basel, den 20. Januar PD Dr. Elisabeth Zemp Stutz Prof. Dr. Martin Birkh\u00e4user Basel, den 20. Januar 2004 Prof. Dr. Marcel Tanner Bodmer, Dr. Christian De Bodmer, Dr. Christian De diensten menopausal woman is (...) not normal; she suffers from a deficiency disease with serious sequelae and needs treatment. \" 1) und heute... 1) Wilson RA, Brevetti RE, Wilson TA. Specific procedures for the elimination of the menopause. West J mit Cimicifuga racemosa 21 22 24 Summary 1. 2. 3. Background and aims Epidemiological study Clinical study with Cimicifuga racemosa 27 28 29 Teil 1 Einleitung und Zielsetzung 1. 1.1. 1.2. 1.3. 2. 1.1. 1.2. 1.3. 1.4. 1.4.1. 1.4.2. 2. 2.1. 2.2. 2.3. 2.4. 2.5. 2.6. Studienpopulation 47 47 54 54 55 55 55 56 56 56 57 58 58 59 59 60 63 64 64 Inhaltsverzeichnis 9Inhaltsverzeichnis Seite Abk\u00fcrzungen mit Cimicifuga racemosa 21 22 24 Summary 1. 2. 3. Background and aims Epidemiological study Clinical study with Cimicifuga racemosa 27 28 29 Teil 1 Einleitung und Zielsetzung 1. 1.1. 1.2. 1.3. 2. 1.1. 1.2. 1.3. 1.4. 1.4.1. 1.4.2. 2. 2.1. 2.2. 2.3. 2.4. 2.5. 2.6. Studienpopulation 47 47 54 54 55 55 55 56 56 56 57 58 58 59 59 60 63 64 64 64 66 70 76 79 79 80 87 91 91 96 96 102 106 111 119 123 123 124 125 125 126 128 128 129 130 130 131 133 135 137 138 138 138 139 140 140 142 142 143 145 145 146 151 151 151 154 155 157 157 158 160 160 64 64 66 70 76 79 79 80 87 91 91 96 96 102 106 111 119 123 123 124 125 125 126 128 128 129 130 130 131 133 135 137 138 138 138 139 140 140 142 142 143 145 145 146 151 151 151 154 155 157 157 158 160 160 161 Inhaltsverzeichnis 13Teil Variablen 167 171 171 171 174 174 175 176 176 176 177 177 178 178 178 179 180 180 181 181 181 182 182 182 182 183 183 183 183 184 Aspekte 186 187 187 187 188 188 188 189 189 189 190 191 192 192 192 192 192 193 193 194 194 195 196 196 198 199 201 201 201 201 202 202 202 203 204 204 Inhaltsverzeichnis 13Teil Variablen 167 171 171 171 174 174 175 176 176 176 177 177 178 178 178 179 180 180 181 181 181 182 182 182 182 183 183 183 183 184 Aspekte 186 187 187 187 188 188 188 189 189 189 190 191 192 192 192 192 192 193 193 194 194 195 196 196 198 199 201 201 201 201 202 202 202 203 204 204 Inhaltsverzeichnis der Hitzewallungen 204 205 205 206 206 206 206 207 208 208 209 209 210 210 211 211 211 212 213 213 215 218 226 227 228 228 228 234 239 240 240 255 256 265 267 269 269 269 269 272 272 272 273 274 279 279 280 281 282 283 284 285 286 287 291 Lebenslauf der Hitzewallungen 204 205 205 206 206 206 206 207 208 208 209 209 210 210 211 211 211 212 213 213 215 218 226 227 228 228 228 234 239 240 240 255 256 265 267 269 269 269 269 272 272 272 273 274 279 279 280 281 282 283 284 285 286 287 ICH International conference on harmonization (of technical requirements for registration of pharmaceuticals for human use) IKS Interkantonale Kontrollstelle Intention-to-treat-Kollektiv - randomisiert im Verh\u00e4ltnis 2:1 beinhaltete und Intention-to-treat-Kollektiv - randomisiert im Verh\u00e4ltnis 2:1 beinhaltete und Background and aims Vasomotor, psychological and somatic disorders are associated with the menopausal transition period. The most important symptoms are hot flashes, sweating, depressed mood, sleeping disorders and urogenital complaints. These symptoms are widespread with prevalences between 60% and 80% while duration and severity show a broad range. Hormone replacement therapy was a widely used and accepted treatment of these disturbances in the last decades. The results of numerous randomized clinical trials demonstrate efficacy and safety during short term use. How-ever, newer observational and intervention studies suggest higher risks than presumed so far for longer term hormone administration. Thus women and physicians increasingly look for alternative treatment approaches. Phytotherapy is more frequently used for relief of climacteric symptoms dur-ing the past years and black cohosh root extracts (Cimicifugae racemosae rhizome) are discussed as most important treatment alternative. Preclinical studies suggest that these plant extracts exert tissue specific estrogenic ef-fects. They may show agonistic actions regarding bone and central nervous system and antagonistic (or no) actions regarding uterus and breast. Addi- tionally dopaminergic effects - mediated via D 2 or D 3 receptors - as well as serotonergic and progestogenic effects are proposed. Because of insufficient data for non-hormonal treatments regarding epidemi-ology, safety and efficacy, two aims were pursued with the present work: 1. to conduct an epidemiological survey investigating prevalences of differ- ent treatment regimens for climacteric symptoms, particularly type and fre-quency of the used non-hormonal approaches, and determining predictors on the basis of specific variables for the resulting prevalences 2. to carry out a clinical study that compares efficacy and safety of a black cohosh root extract with placebo in patients with menopausal disorders ac- cording to actual GCP guidelines. Summary 282. Epidemiological study A cross-sectional study was conducted by means of a written survey of a random sample of 950 Swiss women, aged 50-59 years and residing in the city of Basel. The overall response rate was 63%. This was the first investi-gation in Switzerland to determine prevalence and predictors of non-hormonal treatment regimens for climacteric disorders. The questionnaire covered information on sociodemographic characteristics, health related as-pects, anamnestic data regarding diseases and medications, therapeutic cri-teria in relation to menopausal symptoms and attitudes to menopausal tran- sition phase. Three main hypotheses were tested biometrically - 1. lower intensity of cli-macteric disorders favors the use of non-hormonal therapy , 2. women with good self-rated health rather use non-hormonal therapy compared with those who feel less well and 3. women who consider the menopause a natu-ral event rather use non-hormonal or no therapy than those who associate the climacteric transition phase with a medical condition. Further hypotheses were analysed on the basis of documented informations. 44% of the participants used a therapeutic regimen for menopausal symp-toms; 12% were non-hormonal therapies, 28% hormone replacement thera-pies and 4% combinations of the two modalities. 56% of the women reported no treatment. The most frequently used non-hormonal measure was phyto- therapy such as black cohosh extracts, followed by prophylactic regimens for osteoporosis, e.g. calcium preparations, then antidepressants and homeo-pathic drugs. Two third of the women experienced climacteric disorders. Somato-vege-tative symptoms were most frequently observed followed by psychological and urogenital complaints. Main symptoms were hot flashes, sleeping disor- ders, joint and muscle aches, impaired memory and physical performance, nervousness, irritability and depressive mood. Particularly women who were of the opinion that health disorders increasingly occur during the meno-pausal transition phase or who were more heavily burdened by corporel changes exhibited menopausal complaints. Physical health and psychic well-being were strongly affected by climacteric symptoms. Two third of the participants applying either non-hormonal therapies or a combination regimen rated their efficacy as moderate to very good while hormone users reported a much higher rate of over 90%. Predictors for the use of non-hormonal therapies were physical activity, ab-sence of gynecological surgery such as hysterectomy and/or bilateral missing premenstrual syndrome, premenopause, no gynecological Summary 27Summary 1. Background and aims Vasomotor, psychological and somatic disorders are associated with the menopausal transition period. The most important symptoms are hot flashes, sweating, depressed mood, sleeping disorders and urogenital complaints. These symptoms are widespread with prevalences between 60% and 80% while duration and severity show a broad range. Hormone replacement therapy was a widely used and accepted treatment of these disturbances in the last decades. The results of numerous randomized clinical trials demonstrate efficacy and safety during short term use. How-ever, newer observational and intervention studies suggest higher risks than presumed so far for longer term hormone administration. Thus women and physicians increasingly look for alternative treatment approaches. Phytotherapy is more frequently used for relief of climacteric symptoms dur-ing the past years and black cohosh root extracts (Cimicifugae racemosae rhizome) are discussed as most important treatment alternative. Preclinical studies suggest that these plant extracts exert tissue specific estrogenic ef-fects. They may show agonistic actions regarding bone and central nervous system and antagonistic (or no) actions regarding uterus and breast. Addi- tionally dopaminergic effects - mediated via D 2 or D 3 receptors - as well as serotonergic and progestogenic effects are proposed. Because of insufficient data for non-hormonal treatments regarding epidemi-ology, safety and efficacy, two aims were pursued with the present work: 1. to conduct an epidemiological survey investigating prevalences of differ- ent treatment regimens for climacteric symptoms, particularly type and fre-quency of the used non-hormonal approaches, and determining predictors on the basis of specific variables for the resulting prevalences 2. to carry out a clinical study that compares efficacy and safety of a black cohosh root extract with placebo in patients with menopausal disorders ac- cording to actual GCP guidelines. Summary 282. Epidemiological study A cross-sectional study was conducted by means of a written survey of a random sample of 950 Swiss women, aged 50-59 years and residing in the city of Basel. The overall response rate was 63%. This was the first investi-gation in Switzerland to determine prevalence and predictors of non-hormonal treatment regimens for climacteric disorders. The questionnaire covered information on sociodemographic characteristics, health related as-pects, anamnestic data regarding diseases and medications, therapeutic cri-teria in relation to menopausal symptoms and attitudes to menopausal tran- sition phase. Three main hypotheses were tested biometrically - 1. lower intensity of cli-macteric disorders favors the use of non-hormonal therapy , 2. women with good self-rated health rather use non-hormonal therapy compared with those who feel less well and 3. women who consider the menopause a natu-ral event rather use non-hormonal or no therapy than those who associate the climacteric transition phase with a medical condition. Further hypotheses were analysed on the basis of documented informations. 44% of the participants used a therapeutic regimen for menopausal symp-toms; 12% were non-hormonal therapies, 28% hormone replacement thera-pies and 4% combinations of the two modalities. 56% of the women reported no treatment. The most frequently used non-hormonal measure was phyto- therapy such as black cohosh extracts, followed by prophylactic regimens for osteoporosis, e.g. calcium preparations, then antidepressants and homeo-pathic drugs. Two third of the women experienced climacteric disorders. Somato-vege-tative symptoms were most frequently observed followed by psychological and urogenital complaints. Main symptoms were hot flashes, sleeping disor- ders, joint and muscle aches, impaired memory and physical performance, nervousness, irritability and depressive mood. Particularly women who were of the opinion that health disorders increasingly occur during the meno-pausal transition phase or who were more heavily burdened by corporel changes exhibited menopausal complaints. Physical health and psychic well-being were strongly affected by climacteric symptoms. Two third of the participants applying either non-hormonal therapies or a combination regimen rated their efficacy as moderate to very good while hormone users reported a much higher rate of over 90%. Predictors for the use of non-hormonal therapies were physical activity, ab-sence of gynecological surgery such as hysterectomy and/or bilateral missing premenstrual syndrome, premenopause, no gynecological Summary 29consultation, alternative consultation of physicians or other therapists, cli- macteric disorders in the social environment and negative attitude to treat-ment with hormones and - in some degree - breast or endometrium cancer. The following variables of the three main hypotheses turned not out to be predictors for the use of non-hormonal therapies, i.e. self rated health, psy-chic well-being and intensity of somato-vegetative or psychological climac- teric symptoms, and attitude to menopause as a natural event. The last mentioned criterion was associated with no use of therapies in spite of dis-orders. However, milder urogenital symptoms revealed a tendency in favor of the application of non-hormonal therapies. Non-hormonal treatments for menopausal complaints were often taken poly-pragmatically, on a short term basis, mostly for further indications or for gen- eral health promotion. They were rated as moderately efficacious and rarely taken because of a gynecological recommendation. The users of such the-rapies had a relatively low psychic well-being and showed a rather negative attitude to the menopausal transition phase. 3. Clinical study with Cimicifuga racemosa A multicenter, randomized, placebo-controlled, double-blind, parallel group study was conducted in peri- or early postmenopausal women aged 45 to 60 years with t3 hot flashes daily. The trial consisted of a 2-week run-in phase and a 12-week therapy phase. There were 5 assessments: week -2 (screen-ing), week 0 (baseline), weeks 4 and 8 and week 12 (end of treatment). The intention-to-treat population - randomized in the ratio of 2:1 - consisted of 81 and 41 patients in the Cimicifuga racemosa and the placebo group, respec-tively. Two main outcome measures were defined: hot flashes as cardinal symp-tom, e.g. a composite score taking into account number and severity of the hot flashes - weekly weighted score - and the Kupperman Index, a validated and internationally used climacteric symptom list. Furthermore, secondary outcome measures were evaluated such as the Menopause Rating Scale, urogenital and ophthalmic symptoms, FSH serum level, karyopyknotic index and as safety criteria routine laboratory parameters and adverse events. Summary 30In the primary multivariate efficacy analysis no superiority of the tested black cohosh extract compared to placebo could be demonstrated regarding the weekly weighted score of hot flashes and the Kupperman Index. However, the analysis of the subgroup of patients with climacteric com-plaints of at least moderate intensity at the beginning of treatment, exhibiting a Kupperman Index of t20, showed a statistically significant superiority of Cimicifuga racemosa compared to placebo concerning this index. A de- crease of 47% was observed in the black cohosh group, whereas the reduc-tion in the placebo group was 21% (P=0,018). The weekly weighted score of hot flashes decreased by 53% and 25% in the active and placebo group, re-spectively - with a trend towards statistical significance (P=0,052). Concern- ing the Menopause Rating Scale, the active group showed again a statisti- cally significant superiority in comparison with the placebo group (P=0,009). The score values decreased by 48% in the Cimicifuga racemosa group and by 14% in the placebo group. The two assessment instruments for meno-pausal disorders - the Kupperman Index and the Menopause Rating Scale - correlated markedly and produced similar results. The multivariate analysis including all outcome measures resulted in a superiority of the plant extract reaching nearly statistical significance in this subgroup (P=0,053). Likewise in the subgroup of perimenopausal patients the active preparation showed a superiority with a trend towards statistical significance compared to placebo as assessed by the Kupperman Index (P=0,052). There were no differences between the Cimicifuga racemosa group and the placebo group regarding adverse events or safety parameters, such as weight, pulse, blood pressure, karyopyknotic index, hemoglobin, the plant extract group and 10/44 patients (23%) in the placebo group - and intensity were comparable in the two groups. No relevant changes under active or placebo therapy were ob-served according to the safety variables. In particular, the karyopyknotic in- dex showed no proliferative effects on the vaginal epithelium. The results indicate a superiority of the tested Cimicifuga racemosa extract compared to placebo regarding symptoms of menopausal disorders in pa- tients with a Kupperman Index t20, but not in the intention-to-treat popula- tion as a whole. It is suggested that patients suffering from at least moderate complaints show a better therapeutic reaction than patients with symptoms of mild intensity. Summary 29consultation, alternative consultation of physicians or other therapists, cli- macteric disorders in the social environment and negative attitude to treat-ment with hormones and - in some degree - breast or endometrium cancer. The following variables of the three main hypotheses turned not out to be predictors for the use of non-hormonal therapies, i.e. self rated health, psy-chic well-being and intensity of somato-vegetative or psychological climac- teric symptoms, and attitude to menopause as a natural event. The last mentioned criterion was associated with no use of therapies in spite of dis-orders. However, milder urogenital symptoms revealed a tendency in favor of the application of non-hormonal therapies. Non-hormonal treatments for menopausal complaints were often taken poly-pragmatically, on a short term basis, mostly for further indications or for gen- eral health promotion. They were rated as moderately efficacious and rarely taken because of a gynecological recommendation. The users of such the-rapies had a relatively low psychic well-being and showed a rather negative attitude to the menopausal transition phase. 3. Clinical study with Cimicifuga racemosa A multicenter, randomized, placebo-controlled, double-blind, parallel group study was conducted in peri- or early postmenopausal women aged 45 to 60 years with t3 hot flashes daily. The trial consisted of a 2-week run-in phase and a 12-week therapy phase. There were 5 assessments: week -2 (screen-ing), week 0 (baseline), weeks 4 and 8 and week 12 (end of treatment). The intention-to-treat population - randomized in the ratio of 2:1 - consisted of 81 and 41 patients in the Cimicifuga racemosa and the placebo group, respec-tively. Two main outcome measures were defined: hot flashes as cardinal symp-tom, e.g. a composite score taking into account number and severity of the hot flashes - weekly weighted score - and the Kupperman Index, a validated and internationally used climacteric symptom list. Furthermore, secondary outcome measures were evaluated such as the Menopause Rating Scale, urogenital and ophthalmic symptoms, FSH serum level, karyopyknotic index and as safety criteria routine laboratory parameters and adverse events. Summary 30In the primary multivariate efficacy analysis no superiority of the tested black cohosh extract compared to placebo could be demonstrated regarding the weekly weighted score of hot flashes and the Kupperman Index. However, the analysis of the subgroup of patients with climacteric com-plaints of at least moderate intensity at the beginning of treatment, exhibiting a Kupperman Index of t20, showed a statistically significant superiority of Cimicifuga racemosa compared to placebo concerning this index. A de- crease of 47% was observed in the black cohosh group, whereas the reduc-tion in the placebo group was 21% (P=0,018). The weekly weighted score of hot flashes decreased by 53% and 25% in the active and placebo group, re-spectively - with a trend towards statistical significance (P=0,052). Concern- ing the Menopause Rating Scale, the active group showed again a statisti- cally significant superiority in comparison with the placebo group (P=0,009). The score values decreased by 48% in the Cimicifuga racemosa group and by 14% in the placebo group. The two assessment instruments for meno-pausal disorders - the Kupperman Index and the Menopause Rating Scale - correlated markedly and produced similar results. The multivariate analysis including all outcome measures resulted in a superiority of the plant extract reaching nearly statistical significance in this subgroup (P=0,053). Likewise in the subgroup of perimenopausal patients the active preparation showed a superiority with a trend towards statistical significance compared to placebo as assessed by the Kupperman Index (P=0,052). There were no differences between the Cimicifuga racemosa group and the placebo group regarding adverse events or safety parameters, such as weight, pulse, blood pressure, karyopyknotic index, hemoglobin, the plant extract group and 10/44 patients (23%) in the placebo group - and intensity were comparable in the two groups. No relevant changes under active or placebo therapy were ob-served according to the safety variables. In particular, the karyopyknotic in- dex showed no proliferative effects on the vaginal epithelium. The results indicate a superiority of the tested Cimicifuga racemosa extract compared to placebo regarding symptoms of menopausal disorders in pa- tients with a Kupperman Index t20, but not in the intention-to-treat popula- tion as a whole. It is suggested that patients suffering from at least moderate complaints show a better therapeutic reaction than patients with symptoms of mild intensity. Summary 31The Kupperman Index and the Menopause Rating Scale as assessment in- struments seem to cover the whole spectrum of climacteric complaints more adequately and to respond to treatment effects more sensitively than the weekly weighted score focussed solely on hot flashes and sweating. The 3-month treatment with the tested black cohosh extract may be re-garded as safe for women with menopausal complaints according to the analysed safety variables as well as according to frequency and severity of the reported adverse events. Teil 1 Einleitung 33Teil 1 Einleitung 1. Ausgangslage 1.1. die ersten 12 Monate nach der Menopause beschreibt - 2 bis vor-kommen: so die ersten 12 Monate nach der Menopause beschreibt - 2 bis vor-kommen: so Lufkin 1992, Ettinger 1994, Rozenberg 1997, Studd 1996, PEPI Investigators 1995, NIH Consensus Conference 1993, Barrett-Connor 1991, Robinson 1994, Ohkura 1994, Writing Group for the Women's Health Initi-ative Investigators 2002). Bei bereits Alzheimer Vergleich zur Placebo-Gruppe (Writing Group for the Women's Health Initiative Investiga-tors 2002, Shumaker 2003, Wassertheil-Smoller 2003). Auch die Million am gr\u00f6ssten war (Million Women Collaborators Lufkin 1992, Ettinger 1994, Rozenberg 1997, Studd 1996, PEPI Investigators 1995, NIH Consensus Conference 1993, Barrett-Connor 1991, Robinson 1994, Ohkura 1994, Writing Group for the Women's Health Initi-ative Investigators 2002). Bei bereits Alzheimer Vergleich zur Placebo-Gruppe (Writing Group for the Women's Health Initiative Investiga-tors 2002, Shumaker 2003, Wassertheil-Smoller 2003). Auch die Million am gr\u00f6ssten war (Million Women Collaborators Million Women Study ein (Million Women Kronenberg 2002, Russell 2002, Ginsburg 2000, Boblitz 2000, mit der von Placebo vergleichbar war (Huntley Million Women Study ein (Million Women Kronenberg 2002, Russell 2002, Ginsburg 2000, Boblitz 2000, mit der von Placebo vergleichbar war (Huntley T, West L. Randomized placebo-controlled trial of an isoflavone supplement and menopausal symptoms in women. Climacteric 1999;2:85-92. Bacchi-Modena A, Bolis P, Pansini Pisati R, H\u00fcls G. and tolerability of K, Norling B, Larsen S, Arce JC. Do combinations of 1mg estradiol and low doses of NETA effectively control menopausal 1998;1:219-228. Barrett-Connor E. therapy. BMJ 1998;317:457-461. Barrett-Connor E, Bush T. Estrogen and coronary heart JAMA Munk-Jensen N, hormonal replacement therapy: A double-blind, pla- measures. Psycho-ther Psychosom 1998;67:259-265. Beral F, Bull D, Doll R, Key T, Peto R, Reeves G. Breast cancer and hor-mone replacement therapy: collaborative reanalysis of data from 51 epide- miological studies of 52705 women with breast cancer and 108411 women without breast cancer. Lancet 1997;350:1047-1059. T. Drug related negative side-effects is a common reason for poor compliance in hormone replacement therapy. Maturitas 1999;32:77-86. Boblitz Short-term Fertil Steril D. Maximizing the benefit of estrogen therapy for preven-tion of osteoporosis. Menopause 1994;1:19-24. Fitzpatrick LA. Selective Estrogen receptor modulators and phytoestrogens: for the postmenopausal woman. Mayo Clin Proc 1999;74:601-607. Freedman RR, Woodward S. Behavioral treatment of menopausal hot flushes: Evaluation by ambulatory monitoring. Am J J, Prelevic GM. Lack of significant hormonal effects and controlled trials of phyto-oestrogens. Lancet 2000;355:163-164. Gordon SF, Thompson KA, Ruoff GE, Imig JR, Lane PJ, Schwenker CE. with Fertil 1995;40:126- 134. Sowers MF. al. Postmenopausal apy N Engl J Med 1997;336:1769-1775. Guanosine AR, Benedek-Jazman LJ, Hart DM Maturitas T, West L. Randomized placebo-controlled trial of an isoflavone supplement and menopausal symptoms in women. Climacteric 1999;2:85-92. Bacchi-Modena A, Bolis P, Pansini Pisati R, H\u00fcls G. and tolerability of K, Norling B, Larsen S, Arce JC. Do combinations of 1mg estradiol and low doses of NETA effectively control menopausal 1998;1:219-228. Barrett-Connor E. therapy. BMJ 1998;317:457-461. Barrett-Connor E, Bush T. Estrogen and coronary heart JAMA Munk-Jensen N, hormonal replacement therapy: A double-blind, pla- measures. Psycho-ther Psychosom 1998;67:259-265. Beral F, Bull D, Doll R, Key T, Peto R, Reeves G. Breast cancer and hor-mone replacement therapy: collaborative reanalysis of data from 51 epide- miological studies of 52705 women with breast cancer and 108411 women without breast cancer. Lancet 1997;350:1047-1059. T. Drug related negative side-effects is a common reason for poor compliance in hormone replacement therapy. Maturitas 1999;32:77-86. Boblitz Short-term Fertil Steril D. Maximizing the benefit of estrogen therapy for preven-tion of osteoporosis. Menopause 1994;1:19-24. Fitzpatrick LA. Selective Estrogen receptor modulators and phytoestrogens: for the postmenopausal woman. Mayo Clin Proc 1999;74:601-607. Freedman RR, Woodward S. Behavioral treatment of menopausal hot flushes: Evaluation by ambulatory monitoring. Am J J, Prelevic GM. Lack of significant hormonal effects and controlled trials of phyto-oestrogens. Lancet 2000;355:163-164. Gordon SF, Thompson KA, Ruoff GE, Imig JR, Lane PJ, Schwenker CE. with Fertil 1995;40:126- 134. Sowers MF. al. Postmenopausal apy N Engl J Med 1997;336:1769-1775. Guanosine AR, Benedek-Jazman LJ, Hart DM Maturitas 41Hammar M, Berg G, Lindgren R. Does physical exercise influence the fre- double-blind study to evaluate the menopausal vasomotor flushes. DM, Reboussin DM, Brosnihan KB, SA, Snyder TE, CD, Kowalchuk GJ, Stuckey TD, Rogers WJ, Givens DH, Waters D. Effects of estrogen replacement on the progression of coro- Grady D, Bush T, Furberg C, Herrington D, Riggs B, Vittinhoff E. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA 1998;280:605-613. Huntley AL, Ernst E. Soy for the treatment of perimenopausal symptoms - a systematic review. Maturitas 2004;47:1-9. Huntley AL, Ernst E. A systematic review of herbal medicinal products for the treatment of menopausal symptoms. Menopause 2003;10:465-476. Kang HJ, Ansbacher R, Hammoud MM. Use of alternative and complemen-tary medicine in menopause. Int J Gynecol Obstet 2002;79:195-207. Kanis JA, Johnell O, Gullberg B et al . Evidence of efficacy of drugs affecting bone metabolism in preventing hip fracture. BMJ 1992;305:1124-1128. Keller PJ, Maurer-Major E. Hormonsubstitution in der Menopause. Praxis 1997;86:1458-1462. Knight DC, Howes JB, Eden JA. The effect Promensil, an isoflavone ex-tract, on menopausal symptoms. Climacteric 1999;2:79-84. Knight DC, Eden JA. A review of the clinical effects of phytoestrogens. Ob-stet Gynecol YL, McGrath BP, Teede HJ. The effects of soy protein containing phytoestrogens on menopausal symptoms in post-menopausal women. Climacteric 2000;3:161-167. Kronenberg F, Fugh-Bergman A. Complementary and alternative medicine for menopausal symptoms: a review of randomized, controlled trials. Ann Intern Med 2002;137:805-813. Laufer LR, Erlick Y, Meldrun DR, Judd HL. postmenopausal women. Obstet Gynecol 1992;60:583. Liebermann S. Evidence-based natural the effective- ness of Cimicifuga racemosa (Black cohosh) for the symptoms of meno-pause. J Women's Health 1998;7:525-529. Lindgren R, Berg G, Hammar M, Zuccon E. Hormonal replacement therapy and sexuality in a population of Swedish postmenopausal women. bone loss using tibolone or conventional peroral or transdermal hormone replacement therapy with 17 E-estradiol and dydrogesterone. J Mineral Res 1997;12:806-812. Lufkin HW, with transdermal estrogen. Ann Intern Med 1992;117:1-9. Manson JAE, Hsia J, Johnson KC, Rossouw JE, Assaf AR, Lasser NL. Es- trogen plus progestin and the risk of coronary heart disease. N Engl J Med 2003;349:523-534. Matthews KA, Kuller LH, Wing RR, Meilahn EN, Plantinga P. Prior to use of estrogen replacement therapy, are users healthier than nonusers? Am J Epi- demiol 1996;143:971-978. Maxin P, Ettinger B, GM. estrogen treatment. Osteoporos Int 1995;5:23-29. McKinlay SM, Brambilla DJ, Posner JG. The normal menopause transition. Maturitas 1992;14:103-115. McKinney KA, Thompson W. A practical guide to prescribing hormone re-placement therapy. Drugs 1998;56:49-57. Michels KB, Manson JAE. Postmenopausal hormone therapy: a reversal of fortune. Circulation 2003;107:1830-1833. Teil 1 Einleitung 41Hammar M, Berg G, Lindgren R. Does physical exercise influence the fre- double-blind study to evaluate the menopausal vasomotor flushes. DM, Reboussin DM, Brosnihan KB, SA, Snyder TE, CD, Kowalchuk GJ, Stuckey TD, Rogers WJ, Givens DH, Waters D. Effects of estrogen replacement on the progression of coro- Grady D, Bush T, Furberg C, Herrington D, Riggs B, Vittinhoff E. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA 1998;280:605-613. Huntley AL, Ernst E. Soy for the treatment of perimenopausal symptoms - a systematic review. Maturitas 2004;47:1-9. Huntley AL, Ernst E. A systematic review of herbal medicinal products for the treatment of menopausal symptoms. Menopause 2003;10:465-476. Kang HJ, Ansbacher R, Hammoud MM. Use of alternative and complemen-tary medicine in menopause. Int J Gynecol Obstet 2002;79:195-207. Kanis JA, Johnell O, Gullberg B et al . Evidence of efficacy of drugs affecting bone metabolism in preventing hip fracture. BMJ 1992;305:1124-1128. Keller PJ, Maurer-Major E. Hormonsubstitution in der Menopause. Praxis 1997;86:1458-1462. Knight DC, Howes JB, Eden JA. The effect Promensil, an isoflavone ex-tract, on menopausal symptoms. Climacteric 1999;2:79-84. Knight DC, Eden JA. A review of the clinical effects of phytoestrogens. Ob-stet Gynecol YL, McGrath BP, Teede HJ. The effects of soy protein containing phytoestrogens on menopausal symptoms in post-menopausal women. Climacteric 2000;3:161-167. Kronenberg F, Fugh-Bergman A. Complementary and alternative medicine for menopausal symptoms: a review of randomized, controlled trials. Ann Intern Med 2002;137:805-813. Laufer LR, Erlick Y, Meldrun DR, Judd HL. postmenopausal women. Obstet Gynecol 1992;60:583. Liebermann S. Evidence-based natural the effective- ness of Cimicifuga racemosa (Black cohosh) for the symptoms of meno-pause. J Women's Health 1998;7:525-529. Lindgren R, Berg G, Hammar M, Zuccon E. Hormonal replacement therapy and sexuality in a population of Swedish postmenopausal women. bone loss using tibolone or conventional peroral or transdermal hormone replacement therapy with 17 E-estradiol and dydrogesterone. J Mineral Res 1997;12:806-812. Lufkin HW, with transdermal estrogen. Ann Intern Med 1992;117:1-9. Manson JAE, Hsia J, Johnson KC, Rossouw JE, Assaf AR, Lasser NL. Es- trogen plus progestin and the risk of coronary heart disease. N Engl J Med 2003;349:523-534. Matthews KA, Kuller LH, Wing RR, Meilahn EN, Plantinga P. Prior to use of estrogen replacement therapy, are users healthier than nonusers? Am J Epi- demiol 1996;143:971-978. Maxin P, Ettinger B, GM. estrogen treatment. Osteoporos Int 1995;5:23-29. McKinlay SM, Brambilla DJ, Posner JG. The normal menopause transition. Maturitas 1992;14:103-115. McKinney KA, Thompson W. A practical guide to prescribing hormone re-placement therapy. Drugs 1998;56:49-57. Michels KB, Manson JAE. Postmenopausal hormone therapy: a reversal of fortune. Circulation 2003;107:1830-1833. Teil 1 Einleitung 43Million Women Study Collaborators. Breast cancer and hormone-replace- ment therapy in the Million Women Study. Lancet 2003;362:419-427. Mulnard RA, Cotman CW, Doody Koss E, Pfeiffer E, Jin S, Gamst A, Grundman M, Thomas R, Thal LJ. Estrogen replacement therapy for treatment of mild to moderate Alzheimer disease. JAMA 2000;283:1007-1015. Nagamani M, Kelver ME, Smith ER. Treatment of menopausal hot flashes with transdermal administration of clonidine. Am J Huang WC. Norethindrone acetate at 0.5mg dose adds to the efficacy of 1mg 17 -estradiol on vasomotor symp- tom relief. Abstract presented at the 9 th Annual Meeting of the North Ameri- can Menopause Society, Toronto 1998. Ohkura T, Isse K, Akazawa K et al. Low-dose estrogen replacement therapy for Alzheimer disease in women. Menopause 1994;1:125-130. Oldenhave A, Netelenbos C. Pathogenesis Investigators. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. JAMA 1995;273:199- 208. Perz JM. Development of the menopause symptom list: A factor analytical study of menopause associated symptoms. Women and Health 1997;25:53-69. Prelevic GM, Jacobs Knowst J, Sloan J. Evaluation of soy phy-toestrogens for the treatment of hot flashes in breast cancer survivors: a North Central Cancer Treatment Group Trial. J Clin Oncol 2000;18:1068-1074. Robinson D, Friedman L, Marcus R et al: Estrogen replacement therapy and memory in older women. J Geriat Soc 1994;42:9919-922. Teil 1 Einleitung 44Ross RK, Paganini-Hill A, Wan PC, Pike MC. Effect of hormone replacement therapy on breast cancer risk: Estrogen versus estrogen JB, Vandromme J, Kroll M. Educating patients about the benefits and drawbacks of hormone replacement therapy. Drugs Aging 1998;13:33-41. Rozenberg S, Ylikorkala O, Arrenbrecht J Fertil 1997;42(suppl 2):376-387. Russell L, Hicks S, Low AK, Shepherd JM, Brown CA. Phytoestrogens: a viable option? Am J Med Sci 2002;324:185-188. Rymer J, Chapman MG, Fogerlman I. Effect of postmenopausal osteoporosis. Osteoporos Int osteoporosis. J Clin Pharmacol C, Lubin J, L, Hoover R. Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk. JAMA 2000;283:485-491. Schultz-Zehden B, Rosemeier HP. Lydeking-Olsen E. Dietary phytoestrogens and their effect on bone: evidence from in vitro and in vivo, human observational, and dietary intervention studies. Am J Clin Nutr 2003;78(3 Suppl):593S-609S. Shumaker SA, Legault L, Wallace RB. Estrogen plus pro-gestin and the incidence of dementia and mild cognitive impairment in post-menopausal women. JAMA 2003;289:2651-2662. Sowers MR. Menopause: Its epidemiology. In: Goldman MB, Hatch MC, eds. Women and health. Academic press San Diego 2000:1155-1168. Stadberg E, Mattsson LA, Milsom I. The prevalence and severity of climac-teric symptoms and the use of different treatment regimens in a Swedish Collaborators. Breast cancer and hormone-replace- ment therapy in the Million Women Study. Lancet 2003;362:419-427. Mulnard RA, Cotman CW, Doody Koss E, Pfeiffer E, Jin S, Gamst A, Grundman M, Thomas R, Thal LJ. Estrogen replacement therapy for treatment of mild to moderate Alzheimer disease. JAMA 2000;283:1007-1015. Nagamani M, Kelver ME, Smith ER. Treatment of menopausal hot flashes with transdermal administration of clonidine. Am J Huang WC. Norethindrone acetate at 0.5mg dose adds to the efficacy of 1mg 17 -estradiol on vasomotor symp- tom relief. Abstract presented at the 9 th Annual Meeting of the North Ameri- can Menopause Society, Toronto 1998. Ohkura T, Isse K, Akazawa K et al. Low-dose estrogen replacement therapy for Alzheimer disease in women. Menopause 1994;1:125-130. Oldenhave A, Netelenbos C. Pathogenesis Investigators. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. JAMA 1995;273:199- 208. Perz JM. Development of the menopause symptom list: A factor analytical study of menopause associated symptoms. Women and Health 1997;25:53-69. Prelevic GM, Jacobs Knowst J, Sloan J. Evaluation of soy phy-toestrogens for the treatment of hot flashes in breast cancer survivors: a North Central Cancer Treatment Group Trial. J Clin Oncol 2000;18:1068-1074. Robinson D, Friedman L, Marcus R et al: Estrogen replacement therapy and memory in older women. J Geriat Soc 1994;42:9919-922. Teil 1 Einleitung 44Ross RK, Paganini-Hill A, Wan PC, Pike MC. Effect of hormone replacement therapy on breast cancer risk: Estrogen versus estrogen JB, Vandromme J, Kroll M. Educating patients about the benefits and drawbacks of hormone replacement therapy. Drugs Aging 1998;13:33-41. Rozenberg S, Ylikorkala O, Arrenbrecht J Fertil 1997;42(suppl 2):376-387. Russell L, Hicks S, Low AK, Shepherd JM, Brown CA. Phytoestrogens: a viable option? Am J Med Sci 2002;324:185-188. Rymer J, Chapman MG, Fogerlman I. Effect of postmenopausal osteoporosis. Osteoporos Int osteoporosis. J Clin Pharmacol C, Lubin J, L, Hoover R. Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk. JAMA 2000;283:485-491. Schultz-Zehden B, Rosemeier HP. Lydeking-Olsen E. Dietary phytoestrogens and their effect on bone: evidence from in vitro and in vivo, human observational, and dietary intervention studies. Am J Clin Nutr 2003;78(3 Suppl):593S-609S. Shumaker SA, Legault L, Wallace RB. Estrogen plus pro-gestin and the incidence of dementia and mild cognitive impairment in post-menopausal women. JAMA 2003;289:2651-2662. Sowers MR. Menopause: Its epidemiology. In: Goldman MB, Hatch MC, eds. Women and health. Academic press San Diego 2000:1155-1168. Stadberg E, Mattsson LA, Milsom I. The prevalence and severity of climac-teric symptoms and the use of different treatment regimens in a Swedish L. A double-blind, double-dummy, comparative study of Menorest 50 versus Premarin 0.625 mg in the treatment of menopausal symptoms and the prevention of bone loss in patients with menopausal symptoms. Clin Drug Invest 1996;11:205-213. Szanto E, Gruber D, Sator Tang Jacobs D, Stern Y et al. Effect of oestrogen during menopause on risk and age at onset of Alzheimer's disease. Lancet 1996;348:429-432. Upmalis D, Lobo R, Bradley L, Warren M, Cone FL. Vasomotor symptom relief by soy isoflavone extract Isoflavones from red clover (Promensil) sig-nificantly reduce menopausal hot flush symptoms compared with placebo. Maturitas 2002;42:187-193. Waldman TN. Menopause: When hormone replacement therapy is not an option. J Women's Health 1998;7:559-656. Wassertheil-Smoller S, Hendrix S, Limacher M, Heiss G, Kooperberg Ef-fect of women. JAMA 2003;289:2673-2684. Whitlock AP, Valanis B, Ernst D, Smith L. Prevalence of contraindications to hormone replacement therapy in middle-aged women in a managed care setting. J Women's Health 1995;4:293. WHO. Research on the menopause in the 1990s. Technical report series 866. World Health Organization Geneva 1996. Willett WC. Postmenopausal estrogens - opposed, unopposed, JAMA 2000;283:534-535. Witt DM, Lousberg TR. Controversies surrounding estrogen use in post-menopausal women. Ann Pharmacotherapy 1997;31:745-755. Writing Group for the Women's Health Initiative Investigators. Risk and benefits of estrogen plus progestin in healthy M. Effects of acupuncture on cli- macteric symptoms, quality of life and urinary excretion postmenopausal women. Menopause G, Lieberburg I, Grady D. Estrogen therapy in postmeno-pausal women. Effects on cognitive function JAMA L. A double-blind, double-dummy, comparative study of Menorest 50 versus Premarin 0.625 mg in the treatment of menopausal symptoms and the prevention of bone loss in patients with menopausal symptoms. Clin Drug Invest 1996;11:205-213. Szanto E, Gruber D, Sator Tang Jacobs D, Stern Y et al. Effect of oestrogen during menopause on risk and age at onset of Alzheimer's disease. Lancet 1996;348:429-432. Upmalis D, Lobo R, Bradley L, Warren M, Cone FL. Vasomotor symptom relief by soy isoflavone extract Isoflavones from red clover (Promensil) sig-nificantly reduce menopausal hot flush symptoms compared with placebo. Maturitas 2002;42:187-193. Waldman TN. Menopause: When hormone replacement therapy is not an option. J Women's Health 1998;7:559-656. Wassertheil-Smoller S, Hendrix S, Limacher M, Heiss G, Kooperberg Ef-fect of women. JAMA 2003;289:2673-2684. Whitlock AP, Valanis B, Ernst D, Smith L. Prevalence of contraindications to hormone replacement therapy in middle-aged women in a managed care setting. J Women's Health 1995;4:293. WHO. Research on the menopause in the 1990s. Technical report series 866. World Health Organization Geneva 1996. Willett WC. Postmenopausal estrogens - opposed, unopposed, JAMA 2000;283:534-535. Witt DM, Lousberg TR. Controversies surrounding estrogen use in post-menopausal women. Ann Pharmacotherapy 1997;31:745-755. Writing Group for the Women's Health Initiative Investigators. Risk and benefits of estrogen plus progestin in healthy M. Effects of acupuncture on cli- macteric symptoms, quality of life and urinary excretion postmenopausal women. Menopause G, Lieberburg I, Grady D. Estrogen therapy in postmeno-pausal women. Effects on cognitive function und 60 Jahren ange-geben (Wysowski 1995, Keating 1999, 1994, der und 60 Jahren ange-geben (Wysowski 1995, Keating 1999, 1994, der 1998, Ringa 1999, Brett 1997, Mathews 1996, ton 1997). bis 62 1998, Ringa 1999, Brett 1997, Mathews 1996, ton 1997). bis 62 Basis der Basis der dem Erhebungs- instrument zum Lebensstilprojekt (Abel 1999) und dem der 1000 Frauen-Studie (Schultz-Zehden 1998). Die Fragen in Zusammenhang mit den dem Erhebungs- instrument zum Lebensstilprojekt (Abel 1999) und dem der 1000 Frauen-Studie (Schultz-Zehden 1998). Die Fragen in Zusammenhang mit den 232 317 1) 118 232 317 1) 118 0 und 15, urogenitalen und 0 und 15, urogenitalen und 50 50 50 lo quar 52 52 52 median 54 55 55 up quar 57 57 57 max 59 59 59 total 9432) und einen Body Mass Index von 24,5 kg/m 2 auf. Die entsprechenden Mediane lagen bei 165 kg und 23,5 kg/m2. Bei 61,9% des Studienkol- lektivs war der t25 50 50 50 lo quar 52 52 52 median 54 55 55 up quar 57 57 57 max 59 59 59 total 9432) und einen Body Mass Index von 24,5 kg/m 2 auf. Die entsprechenden Mediane lagen bei 165 kg und 23,5 kg/m2. Bei 61,9% des Studienkol- lektivs war der t25 16,9 lo quar 52 160 57 21,1 median 54 165 64 23,5 up quar 57 168 73 26,7 max 59 178 113 39,9 total 950 9461) 9322) 9313) 1) 16,9 lo quar 52 160 57 21,1 median 54 165 64 23,5 up quar 57 168 73 26,7 max 59 178 113 39,9 total 950 9461) 9322) 9313) 1) n % n n % praktisch jeden Tag 33 3,5 60 n % n n % praktisch jeden Tag 33 3,5 60 40,1 Jahren. Der Median betrug 40 Jahre mit einem Minimum bei 22 Jahren und 56 40,1 Jahren. Der Median betrug 40 Jahre mit einem Minimum bei 22 Jahren und 56 die Symptome nicht psychische und urogenitale Symptome: je Minimum 0 und Maximum 9) die Symptome nicht psychische und urogenitale Symptome: je Minimum 0 und Maximum 9) 3 t4 n % n % n % n % Hormone 202 67,1 54 17,9 23 7,6 22 7,3 3 t4 n % n % n % n % Hormone 202 67,1 54 17,9 23 7,6 22 7,3 3 t4 n % n % n % n % Fussreflexzonenmassage 0 0,0 4 21,1 5 26,3 15 31,9 8 17,0 17 36,2 47 total 243 bei Hormonverwenderinnen und 3 t4 n % n % n % n % Fussreflexzonenmassage 0 0,0 4 21,1 5 26,3 15 31,9 8 17,0 17 36,2 47 total 243 bei Hormonverwenderinnen und psychische und urogenitale Symptome: je Minimum 0 und Maximum 9) psychische und urogenitale Symptome: je Minimum 0 und Maximum 9) 19) H+N Hormone und nicht hormonelle The- rapiemassnahmen (total 33) H Hormone (total 246, missing 22) 2) Minimum, 1. Quartil, Median, 3. Quartil, Maximum, Ausreisser 19) H+N Hormone und nicht hormonelle The- rapiemassnahmen (total 33) H Hormone (total 246, missing 22) 2) Minimum, 1. Quartil, Median, 3. Quartil, Maximum, Ausreisser am Hormone und nicht hormonelle The- rapiemassnahmen (total 33) H Hormone (total 246, missing 22) 2) Minimum, 1. Quartil, Median, 3. Quartil, Maximum, Ausreisser Hormone und nicht hormonelle The- rapiemassnahmen (total 33) H Hormone (total 246, missing 22) 1) Beschwerden in Zusammenhang mit Sexualit\u00e4t, Harnwegsbeschwerden, Trockenheit der Scheide Minimum, Quartil, Median, 3. Maximum, am Hormone und nicht hormonelle The- rapiemassnahmen (total 33) H Hormone (total 246, missing 22) 2) Minimum, 1. Quartil, Median, 3. Quartil, Maximum, Ausreisser Hormone und nicht hormonelle The- rapiemassnahmen (total 33) H Hormone (total 246, missing 22) 1) Beschwerden in Zusammenhang mit Sexualit\u00e4t, Harnwegsbeschwerden, Trockenheit der Scheide Minimum, Quartil, Median, 3. Quartil, Maximum, 164, missing 2) N nicht hormonelle Therapiemassnahmen (total 112, missing 4) H+N Hormone und nicht hormonelle The- rapiemassnahmen (total 33) H Hormone (total 266, missing 2) 2) Minimum, 1. Quartil, Median, 3. Quartil, Maximum, Ausreisser nicht hormonelle Therapiemassnahmen 112, missing 4) H+N Hormone und nicht hormonelle The-rapiemassnahmen (total 33) H Hormone (total 266, missing 2) K N H+N H 1) depressive Verstimmungen, Nervosit\u00e4t/Reizbarkeit, allgemeine Leistungs-/Ged\u00e4chtnisminderung 2) Minimum, Quartil, 164, missing 2) N nicht hormonelle Therapiemassnahmen (total 112, missing 4) H+N Hormone und nicht hormonelle The- rapiemassnahmen (total 33) H Hormone (total 266, missing 2) 2) Minimum, 1. Quartil, Median, 3. Quartil, Maximum, Ausreisser nicht hormonelle Therapiemassnahmen 112, missing 4) H+N Hormone und nicht hormonelle The-rapiemassnahmen (total 33) H Hormone (total 266, missing 2) K N H+N H 1) depressive Verstimmungen, Nervosit\u00e4t/Reizbarkeit, allgemeine Leistungs-/Ged\u00e4chtnisminderung 2) Minimum, Quartil, 164, missing 2) N nicht hormonelle Therapiemassnahmen 112, missing 4) H+N Hormone und nicht hormonelle The-rapiemassnahmen (total 33) H Hormone (total 266, missing 2) 1) Beschwerden in Zusammenhang mit Sexualit\u00e4t, Harnwegsbeschwerden, Trockenheit der (total -80 -60 -40 -20 0 vor Therapie 164, missing 2) N nicht hormonelle Therapiemassnahmen 112, missing 4) H+N Hormone und nicht hormonelle The-rapiemassnahmen (total 33) H Hormone (total 266, missing 2) 1) Beschwerden in Zusammenhang mit Sexualit\u00e4t, Harnwegsbeschwerden, Trockenheit der (total -80 -60 -40 -20 0 vor Therapie Gruppe (total (total -80 -60 -40 -20 0 20 40 60 8012345678910111213141516 Gruppe (total (total -80 -60 -40 -20 0 20 40 60 8012345678910111213141516 (total -80 -60 -40 -20 0 20 40 60 8012345678910111213141516 (total -80 -60 -40 -20 0 20 40 60 8012345678910111213141516 (total -80 -60 -40 -20 0 20 40 60 8012345678910111213141516 (total -80 -60 -40 -20 0 20 40 60 8012345678910111213141516 0- 6 0- 4 0- 2 0 0 2 0 4 0 0- 6 0- 4 0- 2 0 0 2 0 4 0 der Symptomengruppen zwischen Hormone und nicht hormonelle The-rapiemassnahmen (total 33) H Hormone (total 244, missing 24) 2) Minimum, 1. Quartil, Median, 3. Quartil, Maximum, Ausreisser Hormone und nicht hormonelle The- rapiemassnahmen (total 33) H Hormone (total 244, missing 24) N H+N H 1) depressive der Symptomengruppen zwischen Hormone und nicht hormonelle The-rapiemassnahmen (total 33) H Hormone (total 244, missing 24) 2) Minimum, 1. Quartil, Median, 3. Quartil, Maximum, Ausreisser Hormone und nicht hormonelle The- rapiemassnahmen (total 33) H Hormone (total 244, missing 24) N H+N H 1) depressive 22) H+N Hormone und nicht hormonelle The- rapiemassnahmen (total 33) H Hormone (total 244, missing 24) -8 9 Teil 22) H+N Hormone und nicht hormonelle The- rapiemassnahmen (total 33) H Hormone (total 244, missing 24) -8 9 Teil % n % n % n % Rezept/Empfehlung Frauenarzt 28 25,7 15 3 16 34 Hormone 4) missing: 7 5) 8 6) missing: H3) total n % n % n % n % nur Wechseljahrbeschwerden 43 39,5 12 38,7 nicht hormonelle Therapiemassnahmen 3) H Hormone 4) missing 7 5) missing 2 6) missing 18 7) missing 27 Gut die H\u00e4lfte % n % n % n % Rezept/Empfehlung Frauenarzt 28 25,7 15 3 16 34 Hormone 4) missing: 7 5) 8 6) missing: H3) total n % n % n % n % nur Wechseljahrbeschwerden 43 39,5 12 38,7 nicht hormonelle Therapiemassnahmen 3) H Hormone 4) missing 7 5) missing 2 6) missing 18 7) missing 27 Gut die H\u00e4lfte H3) total n % n % n % n % Pr\u00e4vention von Harninkontinenz 9 15,0 6 Hormone 4) missing: 6 5) missing: 2 6) missing: 11 7) missing: 19 In allen 3 Gruppen ben\u00fctzten in H3) total n % n % n % n % Pr\u00e4vention von Harninkontinenz 9 15,0 6 Hormone 4) missing: 6 5) missing: 2 6) missing: 11 7) missing: 19 In allen 3 Gruppen ben\u00fctzten in Beschwerden 19 46,4 Beschwerden 19 46,4 0,05, als 0,05, als 0,05, 0,05, 0,05, 0,05, 0,05, 0,05, 0,05, 0,05, - und der der - und der der OR OR OR OR Phytotherapeutika wie Dong Quai in den USA (Keenan 2003, Newton 2002, Kaufert 1998) genannt. Die Behandlungsdauer war bei Phytotherapeutika wie Dong Quai in den USA (Keenan 2003, Newton 2002, Kaufert 1998) genannt. Die Behandlungsdauer war bei Hor-monverwendung (Stadberg 1997, Hammar Untersuchungen (Coda 1999, Keating 1999, Ringa Marks Oddens 1997, Hammar 1996, Barentsen 1999, 1998) k\u00f6nnte im Sinne eines Hor-monverwendung (Stadberg 1997, Hammar Untersuchungen (Coda 1999, Keating 1999, Ringa Marks Oddens 1997, Hammar 1996, Barentsen 1999, 1998) k\u00f6nnte im Sinne eines (Coda Keating 1999, Marks 1998, Oddens 1997, Stadberg 1997, von 2000) (Coda Keating 1999, Marks 1998, Oddens 1997, Stadberg 1997, von 2000) S, Weitkunat R. The Berne-Munich Lifestyle Pa- nel. Background and baseline results from a longitudinal health lifestyle sur-vey. Soz Bundesrepublik in Zahlen 1994, 1995, 1996, 1999, 2001, 2002. Bonn: BAH 1995, 1996, 1997, 2000, 2002, 2003. Bardel A, Wallander MA, Sv\u00e4rdsudd K. Hormonal replacement therapy and symptom reporting in menopausal women. A population-based study of 35-65-year-old women in mid-Sweden. Maturitas 2002;41:7-15. Barentsen R. The climacteric in the Netherlands: a review of Dutch studies on epidemiology, attitudes and use of hormone replacement therapy. Eur J Obstet Van Stiphout FLM. The view of women aged 45-65 and their partners on aspects of the climacteric phase of life. Eur J Obstet Gynecol Reprod Biol 1994;57:95-101. Barlow DH, Grosset KA, Hart H, Hart DM. A study of the experience of Glas-gow women in the climacteric years. Br J Obstet Gynaecol 1989;96:1192-1197. Beral V, Banks E, Reeves G. Evidence from randomised trials on the long-term effects of hormone replacement therapy. Lancet 2002;360:942-944. Bergemann replacement ther- apy: Estimates from a nationally representative 1997;145:536-545. hormonal de substitution en Suisse en 1997. Master-Thesis Universit\u00e4t Basel 1999 (pers\u00f6nliche Mit-teilung). Duetz MS, Abel T, Meier C, Niemann S. Self-rated health, life satisfaction and personal characteristics of post-menopausal women S, Weitkunat R. The Berne-Munich Lifestyle Pa- nel. Background and baseline results from a longitudinal health lifestyle sur-vey. Soz Bundesrepublik in Zahlen 1994, 1995, 1996, 1999, 2001, 2002. Bonn: BAH 1995, 1996, 1997, 2000, 2002, 2003. Bardel A, Wallander MA, Sv\u00e4rdsudd K. Hormonal replacement therapy and symptom reporting in menopausal women. A population-based study of 35-65-year-old women in mid-Sweden. Maturitas 2002;41:7-15. Barentsen R. The climacteric in the Netherlands: a review of Dutch studies on epidemiology, attitudes and use of hormone replacement therapy. Eur J Obstet Van Stiphout FLM. The view of women aged 45-65 and their partners on aspects of the climacteric phase of life. Eur J Obstet Gynecol Reprod Biol 1994;57:95-101. Barlow DH, Grosset KA, Hart H, Hart DM. A study of the experience of Glas-gow women in the climacteric years. Br J Obstet Gynaecol 1989;96:1192-1197. Beral V, Banks E, Reeves G. Evidence from randomised trials on the long-term effects of hormone replacement therapy. Lancet 2002;360:942-944. Bergemann replacement ther- apy: Estimates from a nationally representative 1997;145:536-545. hormonal de substitution en Suisse en 1997. Master-Thesis Universit\u00e4t Basel 1999 (pers\u00f6nliche Mit-teilung). Duetz MS, Abel T, Meier C, Niemann S. Self-rated health, life satisfaction and personal characteristics of post-menopausal women Postmenopausal hormones - therapy for symptoms only. N Engl J Med 2003;348:19. Griffiths F, Jones K. The use of hormone replacement therapy; results of a Hoes AW. Relationships betweeen attitude towards menopause, well-being and medical attention among women aged 45-60 years. Maturitas 1993;17:77-88. Hammar M, Brynhildsen J, Lindgren R, Nedstrand E, Wyon Y. Hormone replacement therapy and previous use of oral contracep-tives among Swedish women. Maturitas 1996;25:193-199. Hauser GA. Neue IW, Dennehy CE, Tsourounis C. Dietary supplement use among menopausal women attending a San Francisco health conference. Meno-pause 2002;9:72-78. Kaufert WH. Women and menopause: beliefs, attitudes, and behaviors. The North American Meno-pause Society 1997 Menopause Survey. Menopause 1998;5:197-2002. Keenan NL, Saralyn M, Fugh-Berman A, Browne D, Kaczmarczyk J. Sever-ity of menopausal symptoms and use of both conventional and complemen-tary/alternative therapies. Menopause 2003;10:507-515. Keating NL, Cleary Use of hor-mone replacement therapy by postmenopausal women in the United States. Ann Intern Med 1999;130:545-553. Kessel B. Alternatives to estrogen for menopausal Biol Med 1998;217:38-44. Kessel B, Duda RB, J et al. The use of antioxidants and unconven-tional alternatives to estrogen in postmenopausal women with and without breat cancer. 5 th Annual Meeting of NAMS (abstract). Menopause 1994;1: 145-146. Teil 2 epidemiologische Untersuchung A. Hormone Use patterns in 51-year old Danish women. Lee C, Yun GS, Dan A. Botanical dietary supplement use in peri- and postmenopausal women. Menopause 2003;10:65-72. Marks N, Shinberg D. Socioeconomic status differences in hormone therapy. Am J Epidemiol 1998;147:581-593. Matthews KA, Kuller LH, Wing RR, Meilahn EN, Plantinga P. Prior to use of estrogen replacement therapy, are users healthier than nonusers? Am J Epi-demiol 1996;143:971-978. Newton KM, Buist DS, Keenan NL, Anderson LA, LaCroix AZ. Use of alter-native therapies for symptoms: results Rutter C, Keenan NL, Anderson LA. Women's beliefs and decisions about hormone replacement therapy. J Women's Health 1997;6:459.465. Oddens BJ, Boulet MJ. Hormone replacement therapy among Danish study on the use of medica-tion for climacteric complaints in Western Europe - Oddens Boulet climacteric been medi- calized? A study on the use of medication for climacteric complaints in four countries. Maturitas 1992;15:171-181. Oldenhave A, Postmenopausal hormones - therapy for symptoms only. N Engl J Med 2003;348:19. Griffiths F, Jones K. The use of hormone replacement therapy; results of a Hoes AW. Relationships betweeen attitude towards menopause, well-being and medical attention among women aged 45-60 years. Maturitas 1993;17:77-88. Hammar M, Brynhildsen J, Lindgren R, Nedstrand E, Wyon Y. Hormone replacement therapy and previous use of oral contracep-tives among Swedish women. Maturitas 1996;25:193-199. Hauser GA. Neue IW, Dennehy CE, Tsourounis C. Dietary supplement use among menopausal women attending a San Francisco health conference. Meno-pause 2002;9:72-78. Kaufert WH. Women and menopause: beliefs, attitudes, and behaviors. The North American Meno-pause Society 1997 Menopause Survey. Menopause 1998;5:197-2002. Keenan NL, Saralyn M, Fugh-Berman A, Browne D, Kaczmarczyk J. Sever-ity of menopausal symptoms and use of both conventional and complemen-tary/alternative therapies. Menopause 2003;10:507-515. Keating NL, Cleary Use of hor-mone replacement therapy by postmenopausal women in the United States. Ann Intern Med 1999;130:545-553. Kessel B. Alternatives to estrogen for menopausal Biol Med 1998;217:38-44. Kessel B, Duda RB, J et al. The use of antioxidants and unconven-tional alternatives to estrogen in postmenopausal women with and without breat cancer. 5 th Annual Meeting of NAMS (abstract). Menopause 1994;1: 145-146. Teil 2 epidemiologische Untersuchung A. Hormone Use patterns in 51-year old Danish women. Lee C, Yun GS, Dan A. Botanical dietary supplement use in peri- and postmenopausal women. Menopause 2003;10:65-72. Marks N, Shinberg D. Socioeconomic status differences in hormone therapy. Am J Epidemiol 1998;147:581-593. Matthews KA, Kuller LH, Wing RR, Meilahn EN, Plantinga P. Prior to use of estrogen replacement therapy, are users healthier than nonusers? Am J Epi-demiol 1996;143:971-978. Newton KM, Buist DS, Keenan NL, Anderson LA, LaCroix AZ. Use of alter-native therapies for symptoms: results Rutter C, Keenan NL, Anderson LA. Women's beliefs and decisions about hormone replacement therapy. J Women's Health 1997;6:459.465. Oddens BJ, Boulet MJ. Hormone replacement therapy among Danish study on the use of medica-tion for climacteric complaints in Western Europe - Oddens Boulet climacteric been medi- calized? A study on the use of medication for climacteric complaints in four countries. Maturitas 1992;15:171-181. Oldenhave A, Jeune B. Prevalence of hormone replacement therapy in a sample of middle-aged women. Maturitas 1988;9:339-345. Potthoff P, Heinemann LA, Schneider HP, Br\u00e9art G. Trends in the use in hormone replacement therapy in eastern France between 1986 and 1993. Eur J Pub-lic Health 1999;9:300-305. Sanit\u00e4tsdepartement des Kantons Basel-Stadt. Rosemeier HP, Schnitker J, Gerbsch S, Turck R. Application and factor analysis of the menopause rating scale (MRS) in a post-marketing surveillance of Climen. Maturitas 2000a;37:113-124. Schneider HP, Heinemann LAJ, Rosemeier HP, Potthoff P, Behre HM. The Menopause Rating Scale (MRS): comparison with Kupperman index and quality-of-life scale SF-36. Climacteric Schneider HP, Heinemann LAJ, Rosemeier HP, Potthoff P, Behre HM. The Menopause Rating Scale (MRS): reliability of scores of menopausal com-plaints. Climacteric 2000c;3:59-64. Schultz-Zehden Gladenbach HK, Bond CM, Taylor RJ. Hormone replacement therapy: a study of women's knowledge and attitudes. Br J Gen Pract 1993;43:365-370. Stadberg E, Mattsson LA, Milsom I. The prevalence and severity of climac-teric symptoms and the use of different treatment regimens in a Swedish population. T, Hemminki E, Uuetela A. Use of hormone replacement therapy in 1976-89 by 45-64 year old Finnish women. J survey on women's knowledge, information sources, and attitudes to menopause and hormone replacement therapy. Menopause 1994;1:39-48. Vashisht A, Domoney CL, Cronje W, Studd JWW. Prevalence and satisfac-tion with complementary therapies and hormone replacement therapy in a specialist menopause clinic. Climacteric 2001;4:250-256. Wysowski DK, Golden R, Burke L. Use of menopausal estrogens and me- droxyprogesterone in B. Prevalence of hormone replacement therapy in a sample of middle-aged women. Maturitas 1988;9:339-345. Potthoff P, Heinemann LA, Schneider HP, Br\u00e9art G. Trends in the use in hormone replacement therapy in eastern France between 1986 and 1993. Eur J Pub-lic Health 1999;9:300-305. Sanit\u00e4tsdepartement des Kantons Basel-Stadt. Rosemeier HP, Schnitker J, Gerbsch S, Turck R. Application and factor analysis of the menopause rating scale (MRS) in a post-marketing surveillance of Climen. Maturitas 2000a;37:113-124. Schneider HP, Heinemann LAJ, Rosemeier HP, Potthoff P, Behre HM. The Menopause Rating Scale (MRS): comparison with Kupperman index and quality-of-life scale SF-36. Climacteric Schneider HP, Heinemann LAJ, Rosemeier HP, Potthoff P, Behre HM. The Menopause Rating Scale (MRS): reliability of scores of menopausal com-plaints. Climacteric 2000c;3:59-64. Schultz-Zehden Gladenbach HK, Bond CM, Taylor RJ. Hormone replacement therapy: a study of women's knowledge and attitudes. Br J Gen Pract 1993;43:365-370. Stadberg E, Mattsson LA, Milsom I. The prevalence and severity of climac-teric symptoms and the use of different treatment regimens in a Swedish population. T, Hemminki E, Uuetela A. Use of hormone replacement therapy in 1976-89 by 45-64 year old Finnish women. J survey on women's knowledge, information sources, and attitudes to menopause and hormone replacement therapy. Menopause 1994;1:39-48. Vashisht A, Domoney CL, Cronje W, Studd JWW. Prevalence and satisfac-tion with complementary therapies and hormone replacement therapy in a specialist menopause clinic. Climacteric 2001;4:250-256. Wysowski DK, Golden R, Burke L. Use of menopausal estrogens and me- droxyprogesterone in R1 R 2 R1 R 2 CH 3 Kaffees\u00e4ure Ferulas\u00e4ure Isoferulas\u00e4ure R1 R 2 R 3 H CH 3 H CH 3 H H H CH 3 H CH 3 OH OH OH H H Fukinols\u00e4ure Cimicifugas\u00e4ure A CH 3 Kaffees\u00e4ure Ferulas\u00e4ure Isoferulas\u00e4ure R1 R 2 R 3 H CH 3 H CH 3 H H H CH 3 H CH 3 OH OH OH H H Fukinols\u00e4ure Cimicifugas\u00e4ure A (41)2) 1x1 Kapsel n n n n -2 0 4 8 12 Wochen Abbildung 3-4 Studiendesign Bei (41)2) 1x1 Kapsel n n n n -2 0 4 8 12 Wochen Abbildung 3-4 Studiendesign Bei -1 0 1 2 3 4 5 6 7 8 9 10 11 12 Eintritt Beginn Anamnese Entscheid \u00fcber Studienabbruch x Abgabe der Patientenkarte -1 0 1 2 3 4 5 6 7 8 9 10 11 12 Eintritt Beginn Anamnese Entscheid \u00fcber Studienabbruch x Abgabe der Patientenkarte wurden Patientin die Tagebuchbl\u00e4tter Woche und und 3 4 6 und Woche 7 und 8 bzw Woche 9 und 10 und Woche 11 und die Art der Studienbeendigung zum schickte wurden Patientin die Tagebuchbl\u00e4tter Woche und und 3 4 6 und Woche 7 und 8 bzw Woche 9 und 10 und Woche 11 und die Art der Studienbeendigung zum schickte 45 Jahren befinden sich knapp 10% und im Alter 45 Jahren befinden sich knapp 10% und im Alter Form des sogenannten Blind Form des sogenannten Blind (m\u00e4ssig), 4 (gut) und 5 (sehr gut) - global. Falls diese mit 1, (m\u00e4ssig), 4 (gut) und 5 (sehr gut) - global. Falls diese mit 1, 1998, Bech 1998, Bacchi-Modena 1997, Committee for Proprietary Medicinal Products (CPMP) 1997, Derman 1995, Wiklund 1991, 1992, Stoll 1987, Jensen vorliegenden Studie fand 1998, Bech 1998, Bacchi-Modena 1997, Committee for Proprietary Medicinal Products (CPMP) 1997, Derman 1995, Wiklund 1991, 1992, Stoll 1987, Jensen vorliegenden Studie fand Wochensummenscore Wochensummenscore SmarTest idv der Run-in-Phase 0) n\u00e4mlich der 15 bis 28 (Woche 4), 43 bis 56 (Woche 8) und 71 bis 84 (Woche mit dem Faktor 2 und der Hitzewallungen mit Faktor aus dem 84. SmarTest idv der Run-in-Phase 0) n\u00e4mlich der 15 bis 28 (Woche 4), 43 bis 56 (Woche 8) und 71 bis 84 (Woche mit dem Faktor 2 und der Hitzewallungen mit Faktor aus dem 84. Therapieintervalls, n\u00e4mlich der Tage 15 bis 28, 43 bis 56 und 71 bis 84 oder im Fall Therapieintervalls, n\u00e4mlich der Tage 15 bis 28, 43 bis 56 und 71 bis 84 oder im Fall Differenz zwischen dem Wert Differenz zwischen dem Wert idv idv 1 wur- den 1 wur- den Somerset S\u00fcdafrika N = 2 schwerwiegende Protokollverst\u00f6sse N = 5 Intention-to-treat-Kollektiv N = 122 bedeutsame Protokollverst\u00f6sse N = 18 Per-protocol-Kollektiv N = 104 Safety-Kollektiv Somerset S\u00fcdafrika N = 2 schwerwiegende Protokollverst\u00f6sse N = 5 Intention-to-treat-Kollektiv N = 122 bedeutsame Protokollverst\u00f6sse N = 18 Per-protocol-Kollektiv N = 104 Safety-Kollektiv racemosa 2 13 151) Placebo 3 5 8 Gesamt 5 18 23 1) Randomisierung 2:1 racemosa 2 13 151) Placebo 3 5 8 Gesamt 5 18 23 1) Randomisierung 2:1 die An- zahl der Hitzewallungen in der nur bei 4 der Placebo-Gruppe erst nach bis der die An- zahl der Hitzewallungen in der nur bei 4 der Placebo-Gruppe erst nach bis der 83 83 81 68 Placebo 45 44 44 41 36 Gesamt 129 127 127 122 104 3.1.3.1. 83 83 81 68 Placebo 45 44 44 41 36 Gesamt 129 127 127 122 104 3.1.3.1. 81 81 81 81 Placebo Alter (Jahre) Gr\u00f6sse 41 41 40 40 40 Bei allen Patientinnen der Auswertungskollektive in der Cimicifuga-racemosa-Gruppe betrug im Median 53 Jahre, in der Placebo-Gruppe gilt f\u00fcr die mediane Pulsfrequenz 124,0 mm Hg, RR Hg) als in der Placebo-Gruppe (RR systolisch 118,5 mm Hg, RR diastolisch Placebo 81 81 81 81 Placebo Alter (Jahre) Gr\u00f6sse 41 41 40 40 40 Bei allen Patientinnen der Auswertungskollektive in der Cimicifuga-racemosa-Gruppe betrug im Median 53 Jahre, in der Placebo-Gruppe gilt f\u00fcr die mediane Pulsfrequenz 124,0 mm Hg, RR Hg) als in der Placebo-Gruppe (RR systolisch 118,5 mm Hg, RR diastolisch Placebo Dauer der klimakterischen Beschwerden bis Behandlungsbe- ginn lag in der Cimicifuga-racemosa-Gruppe bei 24 Monaten und in der Pla-cebo-Gruppe 16,05% 10 24,39% missing 0 0 valid N 81 41 In der Placebo-Gruppe fand sich ein h\u00f6herer 54 79,41% 24 77,42% missing 13 10 valid N 68 31 waren Dauer der klimakterischen Beschwerden bis Behandlungsbe- ginn lag in der Cimicifuga-racemosa-Gruppe bei 24 Monaten und in der Pla-cebo-Gruppe 16,05% 10 24,39% missing 0 0 valid N 81 41 In der Placebo-Gruppe fand sich ein h\u00f6herer 54 79,41% 24 77,42% missing 13 10 valid N 68 31 waren 58,82% 16 51,61% missing 13 10 valid N 68 31 (korrigiert f\u00fcr HE) 1 = 58,82% 16 51,61% missing 13 10 valid N 68 31 (korrigiert f\u00fcr HE) 1 = 12 Zentralnervensystem 10 1 2 2 Schlafst\u00f6rungen 3 D e p r e s s i o n 2 Migr\u00e4ne 2 M\u00fcdigkeit 1 Stress 1 11) Kopfschmerzen 1 11) 11) Trigeminusneuralgie 1 Fazialisparese (wegen Migr\u00e4ne?) 2 Herzrhythmusst\u00f6rungen 1 kardiovaskul\u00e4rer Insult (Status nach) 1 Phlebitis 1 Kn\u00f6chel-/Bein\u00f6deme 11) 21) Nasenbluten 11) Par\u00e4sthesie 11) Venenproblem 11) Gastrointestinaltrakt 3 Magenschmerzen 11) Magenschmerzen, Erbrechen 1 Obstipation 11) Skelett/Muskulatur 10 1 1 2 1 Hiatushernie 1 Knieoperation (Status nach) 1 Trockenheit 1 2 5 3 1 Sinusitis 1 grippaler Infekt 21) 21) 21) 11) Erk\u00e4ltungskrankheit 31) allergica Blut 3 1 Hyperlipid\u00e4mie 2 1 Faktor-V-Mangel 1 Verschiedenes 10 1 1 2 Hypothyreose 4 Strumaoperation G\u00fcrtelrose 11) Zahnabszess 11) Zahnoperation 11) total 56 38 Pat 5 4 Pat 14 11 Pat 16 12 Pat 8 8 Pat 1) vor\u00fcbergehend, Krankheitsende Woche 12 Zentralnervensystem 4 1 1 2 Schlafst\u00f6rungen 1 11) depressive Verstimmung 1 Migr\u00e4ne 2 M\u00fcdigkeit 1 11) 12 Zentralnervensystem 10 1 2 2 Schlafst\u00f6rungen 3 D e p r e s s i o n 2 Migr\u00e4ne 2 M\u00fcdigkeit 1 Stress 1 11) Kopfschmerzen 1 11) 11) Trigeminusneuralgie 1 Fazialisparese (wegen Migr\u00e4ne?) 2 Herzrhythmusst\u00f6rungen 1 kardiovaskul\u00e4rer Insult (Status nach) 1 Phlebitis 1 Kn\u00f6chel-/Bein\u00f6deme 11) 21) Nasenbluten 11) Par\u00e4sthesie 11) Venenproblem 11) Gastrointestinaltrakt 3 Magenschmerzen 11) Magenschmerzen, Erbrechen 1 Obstipation 11) Skelett/Muskulatur 10 1 1 2 1 Hiatushernie 1 Knieoperation (Status nach) 1 Trockenheit 1 2 5 3 1 Sinusitis 1 grippaler Infekt 21) 21) 21) 11) Erk\u00e4ltungskrankheit 31) allergica Blut 3 1 Hyperlipid\u00e4mie 2 1 Faktor-V-Mangel 1 Verschiedenes 10 1 1 2 Hypothyreose 4 Strumaoperation G\u00fcrtelrose 11) Zahnabszess 11) Zahnoperation 11) total 56 38 Pat 5 4 Pat 14 11 Pat 16 12 Pat 8 8 Pat 1) vor\u00fcbergehend, Krankheitsende Woche 12 Zentralnervensystem 4 1 1 2 Schlafst\u00f6rungen 1 11) depressive Verstimmung 1 Migr\u00e4ne 2 M\u00fcdigkeit 1 11) 1 2 Harnwegsinfekt 11) 11) 11) vaginale Trockenheit 1 Respirationssystem 3 1 2 3 Asthma 2 Pollenallergie 1 grippaler Infekt 11) labialis 11) Exanthem (Gesicht) 1 Augenbrennen 11) total 22 18 Pat 3 3 Pat 5 5 Pat 7 6 Pat 6 5 Pat 1) vor\u00fcbergehend, Krankheitsende w\u00e4hrend Therapie 2) Begleiterkrankungen 37 Patien- in der bei 5 (11,4%) in 7 (11,4%) in der 1 2 Harnwegsinfekt 11) 11) 11) vaginale Trockenheit 1 Respirationssystem 3 1 2 3 Asthma 2 Pollenallergie 1 grippaler Infekt 11) labialis 11) Exanthem (Gesicht) 1 Augenbrennen 11) total 22 18 Pat 3 3 Pat 5 5 Pat 7 6 Pat 6 5 Pat 1) vor\u00fcbergehend, Krankheitsende w\u00e4hrend Therapie 2) Begleiterkrankungen 37 Patien- in der bei 5 (11,4%) in 7 (11,4%) in der 12 Analgetika 2 2 5 1 3 Antazida 2 1 1 1 Antiadiposita 1 Antiallergika/Antihistaminika 2 1 Antidepressiva 1 Antihypertonika, Betablocker 10 1 Antiinfektiva 1 2 1 3 Antiinfektiva vaginal 2 1 1 Antikoagulantien 2 Antirheumatika 5 1 3 1 Antirheumatika dermal 1 1 Dermatologika 1 Estrogentherapie vaginal 1 Gyn\u00e4kologika vaginal 1 Grippetherapeutika 5 1 1 Hom\u00f6opathika 3 1 Hypnotika, Sedativa 2 2 1 Immunstimulantien Kortikosteroide Ophthalmika 1 5 Phytotherapeutika vaginal 1 Rhinologika 1 Roborantien Vitamine 1 1 verschiedenes 1 1 2 total 60 37 Pat 7 6 Pat 25 10 Pat 18 9 Pat 17 14 Pat Teil 3 humanpharmakologische Untersuchung 12 Analgetika 1 1 Antazida 1 3 1 Antiallergika/Antihistaminika 1 1 1 1 Antihypertonika, Betablocker 8 Antihypotonika 1 Antiinfektiva 1 2 1 Antikoagulantien 1 Antirheumatika 2 1 Bronchodilatantien 2 2 2 2 Estrogentherapie vaginal 1 Grippetherapeutika 1 Hom\u00f6opathika 1 Hormone 1 Immunstimulantien pflanzliche 1 Kortikosteroide 1 1 1 Kortikosteroide dermal/intraartikul\u00e4r 1 1 1 Migr\u00e4netherapeutika 1 1 1 1 1 Mineralstoffwechselpr\u00e4parate 4 Mucolytika 2 Ophthalmika 1 1 Sedativa 2 Spasmolytika 1 Virustatika dermal 1 Vitamine 1 1 1 1 verschiedenes 1 1 total 27 17 Pat 8 4 Pat 14 9 Pat 14 7 Pat 11 8 Pat Bei der Eintrittsuntersuchung wurden 58 Begleittherapien von 36 Patientinn- nen der 12 Analgetika 2 2 5 1 3 Antazida 2 1 1 1 Antiadiposita 1 Antiallergika/Antihistaminika 2 1 Antidepressiva 1 Antihypertonika, Betablocker 10 1 Antiinfektiva 1 2 1 3 Antiinfektiva vaginal 2 1 1 Antikoagulantien 2 Antirheumatika 5 1 3 1 Antirheumatika dermal 1 1 Dermatologika 1 Estrogentherapie vaginal 1 Gyn\u00e4kologika vaginal 1 Grippetherapeutika 5 1 1 Hom\u00f6opathika 3 1 Hypnotika, Sedativa 2 2 1 Immunstimulantien Kortikosteroide Ophthalmika 1 5 Phytotherapeutika vaginal 1 Rhinologika 1 Roborantien Vitamine 1 1 verschiedenes 1 1 2 total 60 37 Pat 7 6 Pat 25 10 Pat 18 9 Pat 17 14 Pat Teil 3 humanpharmakologische Untersuchung 12 Analgetika 1 1 Antazida 1 3 1 Antiallergika/Antihistaminika 1 1 1 1 Antihypertonika, Betablocker 8 Antihypotonika 1 Antiinfektiva 1 2 1 Antikoagulantien 1 Antirheumatika 2 1 Bronchodilatantien 2 2 2 2 Estrogentherapie vaginal 1 Grippetherapeutika 1 Hom\u00f6opathika 1 Hormone 1 Immunstimulantien pflanzliche 1 Kortikosteroide 1 1 1 Kortikosteroide dermal/intraartikul\u00e4r 1 1 1 Migr\u00e4netherapeutika 1 1 1 1 1 Mineralstoffwechselpr\u00e4parate 4 Mucolytika 2 Ophthalmika 1 1 Sedativa 2 Spasmolytika 1 Virustatika dermal 1 Vitamine 1 1 1 1 verschiedenes 1 1 total 27 17 Pat 8 4 Pat 14 9 Pat 14 7 Pat 11 8 Pat Bei der Eintrittsuntersuchung wurden 58 Begleittherapien von 36 Patientinn- nen der (12,1%) Gruppe und 14 Begleittherapien Run-in-Phase war der Cimicifuga-racemosa-Gruppe mit einem Median von 89 etwas kleiner als in der Placebo-Gruppe mit einem Median von in etwas Kupperman-Index bei Studienbeginn betrug 19 in der Verum-Gruppe (12,1%) Gruppe und 14 Begleittherapien Run-in-Phase war der Cimicifuga-racemosa-Gruppe mit einem Median von 89 etwas kleiner als in der Placebo-Gruppe mit einem Median von in etwas Kupperman-Index bei Studienbeginn betrug 19 in der Verum-Gruppe behandelten l\u00e4nger als 97 Tage - 11 in der Verum- und 4 in der Placebo-Gruppe. Sie 8 in der Cimicifuga-racemosa-Gruppe und 7 in der Placebo-Gruppe -, Placebo zwischen 10 und 69 Tagen ein. der behandelten l\u00e4nger als 97 Tage - 11 in der Verum- und 4 in der Placebo-Gruppe. Sie 8 in der Cimicifuga-racemosa-Gruppe und 7 in der Placebo-Gruppe -, Placebo zwischen 10 und 69 Tagen ein. der lagen bei 12 vor. Zum Zeitpunkt Wo-che 8 und 12 wurden Patientinnen lagen bei 12 vor. Zum Zeitpunkt Wo-che 8 und 12 wurden Patientinnen 125 1500.00.10.20.30.40.50.60.70.80.91.0 0.00.10.20.30.40.50.60.70.80.91.0-100 -75 -50 -25 0 25 50 125 1500.00.10.20.30.40.50.60.70.80.91.0 0.00.10.20.30.40.50.60.70.80.91.0-100 -75 -50 -25 0 25 50 1-Spezifit\u00e4t0.0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1.00.00.10.20.30.40.50.60.70.80.91.0 0.00.10.20.30.40.50.60.70.80.91.00.0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 wurden bei einer Patientin 1-Spezifit\u00e4t0.0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1.00.00.10.20.30.40.50.60.70.80.91.0 0.00.10.20.30.40.50.60.70.80.91.00.0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 wurden bei einer Patientin 125 1500.00.10.20.30.40.50.60.70.80.91.0 0.00.10.20.30.40.50.60.70.80.91.0-100 -75 -50 -25 0 25 50 ITT-KollektivSensitifit\u00e4t 1-Spezifit\u00e4t0.0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1.00.00.10.20.30.40.50.60.70.80.91.0 0.00.10.20.30.40.50.60.70.80.91.00.0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 125 1500.00.10.20.30.40.50.60.70.80.91.0 0.00.10.20.30.40.50.60.70.80.91.0-100 -75 -50 -25 0 25 50 ITT-KollektivSensitifit\u00e4t 1-Spezifit\u00e4t0.0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1.00.00.10.20.30.40.50.60.70.80.91.0 0.00.10.20.30.40.50.60.70.80.91.00.0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 vor. Zum Zeitpunkt Woche 8 und 12 wurden bei Patientinnen vor. Zum Zeitpunkt Woche 8 und 12 wurden bei Patientinnen Bei im Median etwas kleineren Werten Bei im Median etwas kleineren Werten quar 3,800 3,300 7,300 6,400 190,91% 7,200 200,00% 6,400 271,43% valid 81 sich in der Cimicifuga-racemosa-Gruppe quar 3,800 3,300 7,300 6,400 190,91% 7,200 200,00% 6,400 271,43% valid 81 sich in der Cimicifuga-racemosa-Gruppe 0,00% 0 0,00% 0 0,00% 0 0,00% missing 0 1 7 6 valid N 81 80 74 75 Placebo Harnwegsbeschwerden (absolute und prozentuale H\u00e4ufigkeit) Woche 4,88% 2 4,88% 1 2,63% 1 2,70% missing 0 0 3 4 valid N 41 41 38 37 18,52% 11 13,75% 10 13,51% 9 12,00% missing 0 1 7 6 valid N 81 80 74 75 Teil 3 humanpharmakologische Untersuchung mit 7,32% 4 9,76% 4 10,53% 3 8,11% missing 0 0 3 4 valid N 41 41 38 37 14,10% 6 7,79% 6 8,33% 4 5,56% missing 3 4 9 9 valid N 78 77 72 72 Placebo Dyspareunie (absolute und prozentuale H\u00e4ufigkeit) Woche 2,86% 1 2,86% 2 5,88% 1 3,03% missing 6 6 7 8 valid N 35 35 34 33 10,00% 6 7,50% 6 8,11% 5 6,67% missing 1 1 7 6 valid N 80 80 74 75 Teil 3 humanpharmakologische Untersuchung mit 0,00% 0 0,00% 0 0,00% 0 0,00% missing 0 1 7 6 valid N 81 80 74 75 Placebo Harnwegsbeschwerden (absolute und prozentuale H\u00e4ufigkeit) Woche 4,88% 2 4,88% 1 2,63% 1 2,70% missing 0 0 3 4 valid N 41 41 38 37 18,52% 11 13,75% 10 13,51% 9 12,00% missing 0 1 7 6 valid N 81 80 74 75 Teil 3 humanpharmakologische Untersuchung mit 7,32% 4 9,76% 4 10,53% 3 8,11% missing 0 0 3 4 valid N 41 41 38 37 14,10% 6 7,79% 6 8,33% 4 5,56% missing 3 4 9 9 valid N 78 77 72 72 Placebo Dyspareunie (absolute und prozentuale H\u00e4ufigkeit) Woche 2,86% 1 2,86% 2 5,88% 1 3,03% missing 6 6 7 8 valid N 35 35 34 33 10,00% 6 7,50% 6 8,11% 5 6,67% missing 1 1 7 6 valid N 80 80 74 75 Teil 3 humanpharmakologische Untersuchung mit 7,32% 3 7,32% 1 2,63% 1 2,70% missing 0 0 3 4 valid N 41 41 38 37 Abbildung 3-22 zeigt Im Median zeigte sich zum Zeitpunkt Zeitpunkt Cimicifuga-ra-cemosa-Gruppe Median des FSH-Spiegels leicht h\u00f6her als 7,32% 3 7,32% 1 2,63% 1 2,70% missing 0 0 3 4 valid N 41 41 38 37 Abbildung 3-22 zeigt Im Median zeigte sich zum Zeitpunkt Zeitpunkt Cimicifuga-ra-cemosa-Gruppe Median des FSH-Spiegels leicht h\u00f6her als 39,51% 15 36,59% 16 39,02% missing 0 0 0 0 valid N 81 81 41 41 Bez\u00fcglich positiver Bewertung 39,51% 15 36,59% 16 39,02% missing 0 0 0 0 valid N 81 81 41 41 Bez\u00fcglich positiver Bewertung 40 F\u00e4llen in der 23 Behand- 46 in 40 F\u00e4llen in der 23 Behand- 46 in mit 35 Patientinnen in der Verum-Gruppe und 18 Patientinnen in der Placebo-Gruppe mit 35 Patientinnen in der Verum-Gruppe und 18 Patientinnen in der Placebo-Gruppe 1.0 0.9 0.8 0.7 0.6 0.5 0.4 0.3 0.2 0.1 0.0 1.0 0.9 0.8 0.7 0.6 0.5 0.4 0.3 0.2 0.1 1.0 0.9 0.8 0.7 0.6 0.5 0.4 0.3 0.2 0.1 0.0 1.0 0.9 0.8 0.7 0.6 0.5 0.4 0.3 0.2 0.1 im Median bei 27 und nach 12-w\u00f6chiger bei 14, in der Placebo-Gruppe betrugen im Median bei 3,8 und bei um 48% in der und 14% in im Median bei 27 und nach 12-w\u00f6chiger bei 14, in der Placebo-Gruppe betrugen im Median bei 3,8 und bei um 48% in der und 14% in in der Placebo-Gruppe. Diese Ereignisse wurden bei 17 von 83 Patientinnen der von 7 5 Placebo 50% 30% 20% 0 0% 60% 2 in der Placebo-Gruppe. Diese Ereignisse wurden bei 17 von 83 Patientinnen der von 7 5 Placebo 50% 30% 20% 0 0% 60% 2 Magenbrennen vaginalen Blutung Patientinnen (3,6%) in der Cimicifuga-racemosa-Gruppe und bei 1 Patientinnen Placebo-Gruppe Magenbrennen vaginalen Blutung Patientinnen (3,6%) in der Cimicifuga-racemosa-Gruppe und bei 1 Patientinnen Placebo-Gruppe -2 Wo 12 Wo -2 Wo 12 Wo -2 Wo 12 Wo -2 Wo 12 mean 67 68 72 73 126 122 80 77 48 47 95 85 50 50 lo quar 58 58 65 66 114 110 71 68 median 66 67 72 73 124 120 80 76 up quar 74 74 80 80 137 129 87 85 max 120 120 100 119 180 173 130 121 missing 0 4 0 4 0 4 0 4 valid N 83 79 83 79 83 79 83 79 Gewicht (kg) Puls (Schl\u00e4ge/min) RRsys (mmHg) RRdias (mmHg) Placebo Wo -2 Wo 12 Wo -2 Wo 12 Wo -2 Wo 12 Wo -2 Wo 12 mean 67 68 73 72 123 120 77 74 60 52 90 85 50 50 lo quar 61 61 65 64 109 108 70 65 median 65 66 72 69 120 118 76 75 up quar 71 71 79 80 140 134 83 83 max 99 97 98 102 160 189 101 109 missing 0 2 1 2 1 2 1 2 valid N 44 42 43 42 43 42 43 42 K\u00f6rpergewicht, 78,3% 26 78,8% 26 78,8% missing 15 15 12 12 valid 69 69 33 33 Anzahl und Art der Ver\u00e4nderungen des Menstruationsstatus -2 Wo 12 Wo -2 Wo 12 Wo -2 Wo 12 Wo -2 Wo 12 mean 67 68 72 73 126 122 80 77 48 47 95 85 50 50 lo quar 58 58 65 66 114 110 71 68 median 66 67 72 73 124 120 80 76 up quar 74 74 80 80 137 129 87 85 max 120 120 100 119 180 173 130 121 missing 0 4 0 4 0 4 0 4 valid N 83 79 83 79 83 79 83 79 Gewicht (kg) Puls (Schl\u00e4ge/min) RRsys (mmHg) RRdias (mmHg) Placebo Wo -2 Wo 12 Wo -2 Wo 12 Wo -2 Wo 12 Wo -2 Wo 12 mean 67 68 73 72 123 120 77 74 60 52 90 85 50 50 lo quar 61 61 65 64 109 108 70 65 median 65 66 72 69 120 118 76 75 up quar 71 71 79 80 140 134 83 83 max 99 97 98 102 160 189 101 109 missing 0 2 1 2 1 2 1 2 valid N 44 42 43 42 43 42 43 42 K\u00f6rpergewicht, 78,3% 26 78,8% 26 78,8% missing 15 15 12 12 valid 69 69 33 33 Anzahl und Art der Ver\u00e4nderungen des Menstruationsstatus 1 6 0 6 valid N 82 77 44 38 Mit je gleichen Werten von 2,0 und 3,0 -20 0 20 40 60 800.00.10.20.30.40.50.60.70.80.91.0 0.00.10.20.30.40.50.60.70.80.91.0-80 -60 -40 -20 0 20 40 in 1 6 0 6 valid N 82 77 44 38 Mit je gleichen Werten von 2,0 und 3,0 -20 0 20 40 60 800.00.10.20.30.40.50.60.70.80.91.0 0.00.10.20.30.40.50.60.70.80.91.0-80 -60 -40 -20 0 20 40 in Safety-KollektivSensitivit\u00e4t 1 - Spezifit\u00e4t0.0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1.00.00.10.20.30.40.50.60.70.80.91.0 0.00.10.20.30.40.50.60.70.80.91.00.0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1.0 niedrige Zahlenwerte und Abnahme Safety-KollektivSensitivit\u00e4t 1 - Spezifit\u00e4t0.0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1.00.00.10.20.30.40.50.60.70.80.91.0 0.00.10.20.30.40.50.60.70.80.91.00.0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1.0 niedrige Zahlenwerte und Abnahme 40 Rate der Patientinnen mit Zunahmen in der Placebo-Gruppe / Rate der Patientinnen mit Zunahmen 41 der Eintritts- und Abschlussuntersuchung lagen die 40 Rate der Patientinnen mit Zunahmen in der Placebo-Gruppe / Rate der Patientinnen mit Zunahmen 41 der Eintritts- und Abschlussuntersuchung lagen die 41 Werte von ALAT waren bei 8 Patientinnen bei 189U/L. der Abschlussuntersuchung die 41 Werte von ALAT waren bei 8 Patientinnen bei 189U/L. der Abschlussuntersuchung die 44 41 Bei der Eintrittsuntersuchung waren bei 3 humanpharmakologische Untersuchung mit Cimicifuga racemosa -2 valid N + 0 - P exakt min max mean SE H\u00e4moglobin (g/L) Cimicifuga 78 27 10 41 0,1143 -16 11 -1,1 0,66 Placebo 41 18 1,0 1,15 Placebo 41 20 1,06 ASAT (U/L) 38 0,2145 30 0,1 0,75 Placebo 41 17 -24 12 ALAT -1,9 1,08 Placebo 41 16 1 16 In 44 41 Bei der Eintrittsuntersuchung waren bei 3 humanpharmakologische Untersuchung mit Cimicifuga racemosa -2 valid N + 0 - P exakt min max mean SE H\u00e4moglobin (g/L) Cimicifuga 78 27 10 41 0,1143 -16 11 -1,1 0,66 Placebo 41 18 1,0 1,15 Placebo 41 20 1,06 ASAT (U/L) 38 0,2145 30 0,1 0,75 Placebo 41 17 -24 12 ALAT -1,9 1,08 Placebo 41 16 1 16 In 2,44% 0,00% missing 1 82 43 Teil 3 humanpharmakologische Untersuchung mit Cimicifuga behandelten Patientinnen Cimicifuga-racemosa-Gruppe und bei 2,44% 0,00% missing 1 82 43 Teil 3 humanpharmakologische Untersuchung mit Cimicifuga behandelten Patientinnen Cimicifuga-racemosa-Gruppe und bei Kupperman-Index Behand- lungsbeginn mit im Median 19 in der und einem Kupperman-Index t20 lagen mit einem Kupperman-Index Behand- lungsbeginn mit im Median 19 in der und einem Kupperman-Index t20 lagen mit einem Pansini Pisati R, H\u00fcls G. Efficacy and tolerability of MX, new matrix K, Norling B, Larsen S, Arce JC. Do combinations of 1mg estradiol and low doses of NETA effectively hormonal replacement therapy: A double-blind, pla-cebo-controlled of Cimicifuga Life Sciences 2003;73:1215-1229. Borrelli F, Ernst E. Cimicifuga racemosa: a systematic review of its clinical efficacy. Eur J Clin Pharmacol 2002;58:235-241. Burdette and partial agonist of the se-rotonin receptor. J Agric Food Chem racemosa and clarification of nomen- 27-deoxyactein. Nat Prod for a randomized study. Minerva Ginecol 2000;52:1-4. Colditz GA, Miller JN, Mosteller F. Measuring gain in the evaluation of medi-cal technology:The probability of a better outcome. J Technol Assessment Health Care 1988;4:637-642. Committee for Proprietary Medicinal Products (CPMP). Points to consider on hormone replacement therapy. CPMP/EWP/021/97 EMEA, London 1997. Derman RJ, Dawood MY, Stone S. Quality of life during sequential hormone replacement therapy - A placebo-controlled study. Int J Fertil 1995;40(2):73-78. Dog TL, Powell KL, SM. Critical evaluation of the safety Cimici-fuga racemosa in menopause relief. Menopause AG, Eagon PK. Estrogenicity Hepatology 1997;26(4 part2):502A. Freudenstein J, Dasenbrock C, of estrogen dependent mammary gland tumors in Phytomedicine 2000;7(supplement II):13. Gillings D, Koch G. The application of the principle of intention-to-treat to the analysis of clinical trials. Drug Information Journal 1991;25:411-424. Gass R. Klimakterium, Uni-versit\u00e4t Basel 2002 (pers\u00f6nliche Mitteilung). Hauser GA, Ernst U. Evaluation der Hormonersatztherapie in der Perimeno-pause mit dem Menopause rating scale Pansini Pisati R, H\u00fcls G. Efficacy and tolerability of MX, new matrix K, Norling B, Larsen S, Arce JC. Do combinations of 1mg estradiol and low doses of NETA effectively hormonal replacement therapy: A double-blind, pla-cebo-controlled of Cimicifuga Life Sciences 2003;73:1215-1229. Borrelli F, Ernst E. Cimicifuga racemosa: a systematic review of its clinical efficacy. Eur J Clin Pharmacol 2002;58:235-241. Burdette and partial agonist of the se-rotonin receptor. J Agric Food Chem racemosa and clarification of nomen- 27-deoxyactein. Nat Prod for a randomized study. Minerva Ginecol 2000;52:1-4. Colditz GA, Miller JN, Mosteller F. Measuring gain in the evaluation of medi-cal technology:The probability of a better outcome. J Technol Assessment Health Care 1988;4:637-642. Committee for Proprietary Medicinal Products (CPMP). Points to consider on hormone replacement therapy. CPMP/EWP/021/97 EMEA, London 1997. Derman RJ, Dawood MY, Stone S. Quality of life during sequential hormone replacement therapy - A placebo-controlled study. Int J Fertil 1995;40(2):73-78. Dog TL, Powell KL, SM. Critical evaluation of the safety Cimici-fuga racemosa in menopause relief. Menopause AG, Eagon PK. Estrogenicity Hepatology 1997;26(4 part2):502A. Freudenstein J, Dasenbrock C, of estrogen dependent mammary gland tumors in Phytomedicine 2000;7(supplement II):13. Gillings D, Koch G. The application of the principle of intention-to-treat to the analysis of clinical trials. Drug Information Journal 1991;25:411-424. Gass R. Klimakterium, Uni-versit\u00e4t Basel 2002 (pers\u00f6nliche Mitteilung). Hauser GA, Ernst U. Evaluation der Hormonersatztherapie in der Perimeno-pause mit dem Menopause rating scale Lauritzen C, Schneider HPG. Evaluation klimakterischer Beschwerden (Menopause rating Hern\u00e1ndez-Mu\u00f1oz G, Pluchino S. Cimicifuga racemosa for the treatment of hot flushes in women surviving breast cancer. Maturitas 2003;44(suppl1): S59-S65. Huntley A, Ernst E. A systematic review of the safety of black cohosh. Meno-pause 2003;10:58-64. ICH-Biostatistics Guideline. Statistical principles for clinical trials. E9: Statis-tical considerations in the design of clinical trials. Consensus Guideline, 1998. Jacobson JS, Troxel AB, Evans J, Klaus L, Vahdat L, Kinne D, Lo KMS, Moore A, Rosenman PJ, Kaufman EL, Neugut AI, Grann VR. Randomized trial of black cohosh for the treatment of hot flashes among women with a history of breast cancer. J Clin Onc 2001;19:2739-2745. Jarry W. Organ-specific effects of Cimicifuga racemosa (CR) in brain and uterus. 23 rd international LOF-Symposium on phyto-oestrogens. Workshop of the Society for Medicinal Plant Research. Gent 1999. Jensen J, Christiansen C. Dose-response and withdrawal effects on climac-teric symptoms after hormonal replacement A SA, Duke J, Cole-ton M, Kronenberg F. Analysis of thirteen populations of black for Phytomedicine Wetchler BB, Meyer HG. Contemporary therapy of the menopausal syndrome. J Am Med Ass 1959;171:1627-1637. Kupperman HS, Blatt MHG, Wiesbader H, Filler W. Comparative clinical evaluation of estrogenic preparations by the menopausal and amenorrheal indices. J Clin Endocrinol 1953;13:688-703. Lachin JM. 1996;30:1017-1028. Lachin JM. Some large-sample distribution-free estimators and tests for mul- tivariate partially incomplete data from two populations. Stat of black cohosh (Cimicifuga racemosa rhizoma): A 6-month clinical study demonstrates no systemic estrogenic effect. J Women's Health Gender Med 2002;11:163- 174. L\u00f6hning A, Winterhoff H. Neurotransmitter concentrations Hothorn LA, Lehmacher W. Multiple comparisons in drug clinical trials and preclinical assays: A priori ordered hypothesis. In: Vollmar J, ed. Testing principles in clinical and preclinical trials. Biometrie in der chemisch- pharmazeutischen Industrie 6. Stuttgart: Gustav Research in Women's Health: Black cohosh and red clover. Abstract presented at the 3rd World Congress on Medicinal and Aro- matic Plants for Human Welfare, Chiang Mai Thailand 2003. Meier SA. Effekte von Hormonen und Lauritzen C, Schneider HPG. Evaluation klimakterischer Beschwerden (Menopause rating Hern\u00e1ndez-Mu\u00f1oz G, Pluchino S. Cimicifuga racemosa for the treatment of hot flushes in women surviving breast cancer. Maturitas 2003;44(suppl1): S59-S65. Huntley A, Ernst E. A systematic review of the safety of black cohosh. Meno-pause 2003;10:58-64. ICH-Biostatistics Guideline. Statistical principles for clinical trials. E9: Statis-tical considerations in the design of clinical trials. Consensus Guideline, 1998. Jacobson JS, Troxel AB, Evans J, Klaus L, Vahdat L, Kinne D, Lo KMS, Moore A, Rosenman PJ, Kaufman EL, Neugut AI, Grann VR. Randomized trial of black cohosh for the treatment of hot flashes among women with a history of breast cancer. J Clin Onc 2001;19:2739-2745. Jarry W. Organ-specific effects of Cimicifuga racemosa (CR) in brain and uterus. 23 rd international LOF-Symposium on phyto-oestrogens. Workshop of the Society for Medicinal Plant Research. Gent 1999. Jensen J, Christiansen C. Dose-response and withdrawal effects on climac-teric symptoms after hormonal replacement A SA, Duke J, Cole-ton M, Kronenberg F. Analysis of thirteen populations of black for Phytomedicine Wetchler BB, Meyer HG. Contemporary therapy of the menopausal syndrome. J Am Med Ass 1959;171:1627-1637. Kupperman HS, Blatt MHG, Wiesbader H, Filler W. Comparative clinical evaluation of estrogenic preparations by the menopausal and amenorrheal indices. J Clin Endocrinol 1953;13:688-703. Lachin JM. 1996;30:1017-1028. Lachin JM. Some large-sample distribution-free estimators and tests for mul- tivariate partially incomplete data from two populations. Stat of black cohosh (Cimicifuga racemosa rhizoma): A 6-month clinical study demonstrates no systemic estrogenic effect. J Women's Health Gender Med 2002;11:163- 174. L\u00f6hning A, Winterhoff H. Neurotransmitter concentrations Hothorn LA, Lehmacher W. Multiple comparisons in drug clinical trials and preclinical assays: A priori ordered hypothesis. In: Vollmar J, ed. Testing principles in clinical and preclinical trials. Biometrie in der chemisch- pharmazeutischen Industrie 6. Stuttgart: Gustav Research in Women's Health: Black cohosh and red clover. Abstract presented at the 3rd World Congress on Medicinal and Aro- matic Plants for Human Welfare, Chiang Mai Thailand 2003. Meier SA. Effekte von Hormonen und N, Huang WC. Norethindrone acetate at 0.5mg dose adds to the efficacy of 1mg 17 -estradiol on vasomotor symp- tom relief. Abstract presented at the 9th Annual Meeting of the North Ameri- can Menopause Society, Toronto 1998. Oldenhave A, Netelenbos C. Pathogenesis of climacteric extraction. 2001;73:4704-4710. Potthoff P, Heinemann LA, Schneider HP, Rosemeier HP, Hauser GA. Me- nopause-Rating-Skala J, Gerbsch S, Turck R. Applica-tion and factor analysis of the menopause rating scale (MRS) in a post-marketing surveillance of Climen. Maturitas 2000a;37:113-124. Schneider HP, Heinemann LAJ, Rosemeier HP, Potthoff P, Behre HM. The Menopause Rating Scale (MRS): comparison Kupperman and estrogen-dependent tissues. Phytomedicine 2000;7(supplement II):11-12. Shao Y, Harris A, Wang M, Zhang H, Cordell GA, Bowman M, Lemmo E. Triterpene glycosides recurrent events: Nonparametric methods for random interval count data. J Assoc. 1984;79:653-661. Wende K, Thurow Keebler CM. Evaluation of the endocrinologic condition of the female genital tract by Chicago: of Cytology 1997:55-64. Wied GL. Suggested karyopyknosis. Use vaginal smears. Fertil M, von Schoultz B. A new methodological approach to the evaluation of quality of life in postmenopausal women. Maturitas 1992;14:211-224. Wiklund I, Karlberg J. Evaluation of quality of life in clinical trials. Selecting quality-of-life measures. Control Clin Trials 1991;12:204S-216S. World Health Organization. WHO Monographs on selected medicinal plants. Rhizoma cimicifugae racemosae. a double-blind N, Huang WC. Norethindrone acetate at 0.5mg dose adds to the efficacy of 1mg 17 -estradiol on vasomotor symp- tom relief. Abstract presented at the 9th Annual Meeting of the North Ameri- can Menopause Society, Toronto 1998. Oldenhave A, Netelenbos C. Pathogenesis of climacteric extraction. 2001;73:4704-4710. Potthoff P, Heinemann LA, Schneider HP, Rosemeier HP, Hauser GA. Me- nopause-Rating-Skala J, Gerbsch S, Turck R. Applica-tion and factor analysis of the menopause rating scale (MRS) in a post-marketing surveillance of Climen. Maturitas 2000a;37:113-124. Schneider HP, Heinemann LAJ, Rosemeier HP, Potthoff P, Behre HM. The Menopause Rating Scale (MRS): comparison Kupperman and estrogen-dependent tissues. Phytomedicine 2000;7(supplement II):11-12. Shao Y, Harris A, Wang M, Zhang H, Cordell GA, Bowman M, Lemmo E. Triterpene glycosides recurrent events: Nonparametric methods for random interval count data. J Assoc. 1984;79:653-661. Wende K, Thurow Keebler CM. Evaluation of the endocrinologic condition of the female genital tract by Chicago: of Cytology 1997:55-64. Wied GL. Suggested karyopyknosis. Use vaginal smears. Fertil M, von Schoultz B. A new methodological approach to the evaluation of quality of life in postmenopausal women. Maturitas 1992;14:211-224. Wiklund I, Karlberg J. Evaluation of quality of life in clinical trials. Selecting quality-of-life measures. Control Clin Trials 1991;12:204S-216S. World Health Organization. WHO Monographs on selected medicinal plants. Rhizoma cimicifugae racemosae. a double-blind zutreffenden Text e-Mail sfk@atro.ch Institut f\u00fcr Sozial- zutreffenden Text e-Mail sfk@atro.ch Institut f\u00fcr Sozial- der Universit\u00e4t Basel der Universit\u00e4t Basel 42 Bitte wie stark 42 Bitte wie stark Universit\u00e4t Basel Universit\u00e4t Basel der Skala anbringen Beispiel 0.0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1.0 1. Hitzewallungen, Schwitzen I______I______I______I______I______I______I______I______I______I______I keine sehr starke Beschwerden Beschwerden 0.0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1.0 1. Hitzewallungen, Schwitzen I______I______I______I______I______I______I______I______I______I______I der Skala anbringen Beispiel 0.0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1.0 1. Hitzewallungen, Schwitzen I______I______I______I______I______I______I______I______I______I______I keine sehr starke Beschwerden Beschwerden 0.0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1.0 1. Hitzewallungen, Schwitzen I______I______I______I______I______I______I______I______I______I______I der Skala anbringen Beispiel 0.0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1.0 1. Hitzewallungen, Schwitzen I______I______I______I______I______I______I______I______I______I______I keine sehr starke Beschwerden Beschwerden 0.0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1.0 1. Hitzewallungen, Schwitzen I______I______I______I______I______I______I______I______I______I______I der Skala anbringen Beispiel 0.0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1.0 1. Hitzewallungen, Schwitzen I______I______I______I______I______I______I______I______I______I______I keine sehr starke Beschwerden Beschwerden 0.0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1.0 1. Hitzewallungen, Schwitzen I______I______I______I______I______I______I______I______I______I______I Seite der Pr\u00fcfb\u00f6gen in die Kopfzeile ein, entfernen Sie Abreissetikette mit der Patientennummer von der Schachtel der Pr\u00fcfmedikation und in 4 Wochen - minimal in 3 und maximal in 5 Wochen - f\u00fcr die 1. Kontrollkonsultation und tragen Sie diesen Seite der Pr\u00fcfb\u00f6gen in die Kopfzeile ein, entfernen Sie Abreissetikette mit der Patientennummer von der Schachtel der Pr\u00fcfmedikation und in 4 Wochen - minimal in 3 und maximal in 5 Wochen - f\u00fcr die 1. Kontrollkonsultation und tragen Sie diesen der Skala anbringen Beispiel 0.0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1.0 1. Hitzewallungen, Schwitzen I______I______I______I______I______I______I______I______I______I______I keine sehr starke Beschwerden Beschwerden 0.0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1.0 1. Hitzewallungen, Schwitzen I______I______I______I______I______I______I______I______I______I______I der Skala anbringen Beispiel 0.0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1.0 1. Hitzewallungen, Schwitzen I______I______I______I______I______I______I______I______I______I______I keine sehr starke Beschwerden Beschwerden 0.0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1.0 1. Hitzewallungen, Schwitzen I______I______I______I______I______I______I______I______I______I______I der Pr\u00fcfmedikation Hause. Sie den n\u00e4chsten Konsultationstermin in 4 Wochen - minimal in 3 und maximal in 5 Wochen - f\u00fcr die 2. Kontrollkonsultation und tragen Sie diesen der Pr\u00fcfmedikation Hause. Sie den n\u00e4chsten Konsultationstermin in 4 Wochen - minimal in 3 und maximal in 5 Wochen - f\u00fcr die 2. Kontrollkonsultation und tragen Sie diesen der Skala anbringen Beispiel 0.0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1.0 1. Hitzewallungen, Schwitzen I______I______I______I______I______I______I______I______I______I______I keine sehr starke Beschwerden Beschwerden 0.0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1.0 1. Hitzewallungen, Schwitzen I______I______I______I______I______I______I______I______I______I______I der Skala anbringen Beispiel 0.0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1.0 1. Hitzewallungen, Schwitzen I______I______I______I______I______I______I______I______I______I______I keine sehr starke Beschwerden Beschwerden 0.0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1.0 1. Hitzewallungen, Schwitzen I______I______I______I______I______I______I______I______I______I______I der Pr\u00fcfmedikation den n\u00e4chsten Konsultationstermin in 4 - minimal in 3 und maximal in 5 Wochen - f\u00fcr die Abschlussuntersuchung und tragen Sie diesen der Pr\u00fcfmedikation den n\u00e4chsten Konsultationstermin in 4 - minimal in 3 und maximal in 5 Wochen - f\u00fcr die Abschlussuntersuchung und tragen Sie diesen der Skala anbringen Beispiel 0.0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1.0 1. Hitzewallungen, Schwitzen I______I______I______I______I______I______I______I______I______I______I keine sehr starke Beschwerden Beschwerden 0.0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1.0 1. Hitzewallungen, Schwitzen I______I______I______I______I______I______I______I______I______I______I der Skala anbringen Beispiel 0.0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1.0 1. Hitzewallungen, Schwitzen I______I______I______I______I______I______I______I______I______I______I keine sehr starke Beschwerden Beschwerden 0.0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1.0 1. Hitzewallungen, Schwitzen I______I______I______I______I______I______I______I______I______I______I 0 1 2 3 4 5 6 7 8 9 10 1 1 12 Eintritt Beginn S-ASAT, S-Kreatinin x x x x Symptomerfassung klimakterischer Beschwerden Anamnese Entscheid \u00fcber Studienabbruch x Abgabe der Patientenkarte 0 1 2 3 4 5 6 7 8 9 10 1 1 12 Eintritt Beginn S-ASAT, S-Kreatinin x x x x Symptomerfassung klimakterischer Beschwerden Anamnese Entscheid \u00fcber Studienabbruch x Abgabe der Patientenkarte Mahady World Con-gress Me- dicinal and Aromatic Plants, Chiang Mai Thailand 2003 Untersuchung von seroto-nergen Wir- kungen Mahady World Con-gress Me- dicinal and Aromatic Plants, Chiang Mai Thailand 2003 Untersuchung von seroto-nergen Wir- kungen der Cr-Gruppe in E2-Gruppe. Cr bindet search Gent 1999 Untersuchung der estro- genen Wir- kung Freuden-stein Plant Re-search Gent 1999 Untersuchung der proliferati- der Cr-Gruppe in E2-Gruppe. Cr bindet search Gent 1999 Untersuchung der estro- genen Wir- kung Freuden-stein Plant Re-search Gent 1999 Untersuchung der proliferati- Dissertation M\u00fcnster Dissertation M\u00fcnster Tiere je Gruppe 0,1-1000 KG Cr Extrakt auf Uterus, Kno- chen und LH- Spiegel Tiere je Gruppe 0,1-1000 KG Cr Extrakt auf Uterus, Kno- chen und LH- Spiegel des Uterus. Wirkung \u00fcber ERE, als SERM. Liu estrogenregulierten Wir- kung search Gent 1999 Untersuchung der estro-genen Wir- kung von Cr des Uterus. Wirkung \u00fcber ERE, als SERM. Liu estrogenregulierten Wir- kung search Gent 1999 Untersuchung der estro-genen Wir- kung von Cr Tiere 0,1-1000 Cr Extrakt Cr von Cr bewirk- te Cr auf Uterus, Kno- Tiere 0,1-1000 Cr Extrakt Cr von Cr bewirk- te Cr auf Uterus, Kno- Extrakt Extrakt Re- search Gent 1999 Gent 1999 Untersuchung der estro- genen Wir- kung Re- search Gent 1999 Gent 1999 Untersuchung der estro- genen Wir- kung J En- docrinol 2003;149: 351-362 Untersuchung Effekten von Cr auf Uterus, Kno- chen und LH- Spiegel Genexpression (E2-regulierte und J En- docrinol 2003;149: 351-362 Untersuchung Effekten von Cr auf Uterus, Kno- chen und LH- Spiegel Genexpression (E2-regulierte und estrogenregulierten Wir- kung Pflanzen- extrakten und in von Cr bewirk- te estrogenregulierten Wir- kung Pflanzen- extrakten und in von Cr bewirk- te estrogenregulierten des Uterus. Wir- kung estrogenregulierten des Uterus. Wir- kung Kontroll-Gruppe vor (p<0,01). 4 UAW in (knapp ns) als der Cr-Gruppe war die AP stat signifikant Kontroll-Gruppe vor (p<0,01). 4 UAW in (knapp ns) als der Cr-Gruppe war die AP stat signifikant Seite 1 "}